losartan has been researched along with Diabetes Mellitus, Type 2 in 262 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study provided the opportunity to estimate costs associated with ESRD by baseline albuminuria from a United States perspective." | 10.21 | Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. ( Alexander, CM; Carides, GW; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2004) |
| "To compare the blood pressure (BP)-lowering efficacy of a chlorthalidone/amiloride combination pill with losartan, during initial management of JNC 7 Stage I hypertension in patients with type 2 diabetes mellitus." | 9.41 | Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension and diabetes mellitus: results from the PREVER-treatment randomized controlled trial. ( Afiune Neto, A; Alves, JG; Berwanger, O; Bortolotto, LA; Brandão, AA; Castro, I; Cesarino, JE; Chaves, H; Consolim-Colombo, FM; de Sousa, MR; Figueiredo Neto, JA; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gomes, MM; Gus, M; Jardim, PC; Moreira, LB; Nobre, F; Nóbrega, AC; Pereira E Silva, R; Poli-de-Figueiredo, CE; Scala, LCN; Schlatter, RP; Sobral Filho, DC; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2021) |
| "In this randomised, double-blind, placebo-controlled, crossover trial, we recruited adult patients with type 2 diabetes from six diabetology outpatient clinics in northern Italy, with 24 h albuminuria of more than 300 mg despite 100 mg per day losartan therapy, blood pressure of less than 140/90 mm Hg, serum creatinine concentration of less than 2 mg/dL, stable renal function on stable renin-angiotensin system inhibitor therapy with a fixed dose of losartan, parathyroid hormone concentration of 20 pg/mL to <110 pg/mL, serum calcium concentration of less than 9·5 mg/dL, and serum phosphate concentration of less than 5 mg/dL, who had been more than 80% compliant with placebo treatment during a 1 month placebo run-in." | 9.27 | Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. ( Abbate, M; Belviso, A; Bossi, AC; Carrara, F; de Borst, M; Diadei, O; Gaspari, F; Iliev, IP; Parvanova, A; Peraro, F; Perna, A; Podestà, MA; Remuzzi, G; Rubis, N; Ruggenenti, P; Ruggiero, B; Stucchi, N; Trevisan, R; Trillini, M, 2018) |
| "The aim of this study was to assess the antihypertensive efficacy and safety of aliskiren versus ramipril or losartan in hypertensive patients with type 2 diabetes mellitus, microalbuminuria and uncontrolled hypertension, despite the use of optimal conventional antihypertensive therapy." | 9.20 | Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria. ( Creazzo, M; Dalbeni, A; Dattilo, G; Imbalzano, E; Lizio, G; Mandraffino, G; Saitta, A; Sardo, MA; Scarpelli, M; Tomasello, C; Trapani, G, 2015) |
| "The purpose of this study was to compare the effects of benazepril and losartan on endothelial function and vascular stiffness, in patients with diabetes mellitus and hypertension." | 9.20 | Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A randomized controlled trial. ( Bedirian, R; Gismondi, RA; Ladeira, MC; Neves, MF; Oigman, W; Pozzobon, CR, 2015) |
| "The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus." | 9.20 | Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Dario Ragonesi, P; Derosa, G; Franzetti, I; Maffioli, P; Querci, F, 2015) |
| "The aim of this study was to evaluate the effects of lercanidipine or barnidipine on echocardiographic parameters, in hypertensive, type 2 diabetics with left ventricular hypertrophy." | 9.20 | Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. ( D'Angelo, A; Derosa, G; Franzetti, I; Maffioli, P; Mugellini, A; Pesce, RM; Querci, F, 2015) |
| "In this post-hoc analysis of a randomized crossover study, 33 T2DM subjects with albuminuria received either 50 mg of losartan or 20 mg of quinapril (both 50% maximal dose) daily for 4 weeks with 4-week wash-out period in between." | 9.19 | Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients. ( Lim, SC; Liu, JJ; Subramaniam, T; Sum, CF, 2014) |
| " Telmisartan, one of the currently available angiotensin II type 1 receptor blockers (ARBs), has been shown to exert a more powerful proteinuria (albuminuria) reduction in patients with DN, but whether the prominent renoprotective effect of telmisartan is mediated through enhancing antioxidant defense capacity and reducing oxidative stress has not been fully elucidated." | 9.15 | Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. ( Fujishima, H; Fujita, H; Komatsu, K; Morii, T; Narita, T; Sakamoto, T; Takahashi, T; Yamada, Y, 2011) |
| "Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85-105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56)." | 9.14 | Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Wenzel, RR, 2009) |
| "To evaluate effects of 6-month therapy with losartan in combination with indapamide on a clinical course, immunological, metabolic parameters, left ventricular function, exercise tolerance and quality of life in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS)." | 9.14 | [Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus]. ( Bolotskaia, LA; Derbeneva, NV; Frants, MV; Kuznetsova, AV; Lukinov, AV; Maianskaia, SD; Shilov, SN; Stepacheva, TA; Tepliakov, AT; Vdovina, TV, 2009) |
| "A prospective, open label, parallel group and randomized study was conducted to see the effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients." | 9.14 | Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. ( Hoque, R; Iqbal, M; Rahman, MS, 2009) |
| "It is unclear whether serum uric acid (SUA) is associated with development of new-onset diabetes (NOD) in patients with hypertension and left ventricular hypertrophy (LVH)." | 9.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| "The ADHT (Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial) evaluated the efficacy and safety of adding amlodipine to the treatment regimen of patients with hypertension and diabetes who were already receiving either quinapril or losartan as monotherapy." | 9.13 | Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. ( Gregg, AM; Kloner, RA; Neutel, J; Roth, EM; Schwartz, B; Shi, H; Thakker, KM; Weinberger, MH; Weiss, R, 2008) |
| "The study demonstrated that the combination of manidipine and delapril is as effective as losartan and hydrochlorothiazide in treatment of hypertension in type 2 diabetes." | 9.13 | Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Triposkiadis, F; Wenzel, RR, 2008) |
| "In this study we evaluated the effect of a dual blockade with enalapril and losartan on the reduction of overt macroproteinuria and its potential mechanism(s) in hypertensive patients with type 2 diabetes." | 9.12 | Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. ( Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M, 2006) |
| "In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy." | 9.12 | Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007) |
| "Twenty-two type 2 DM patients with microalbuminuria were treated with 50-100 mg/day of Losartan for 6 months." | 9.12 | Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria. ( Berard, L; Hak, D; Khan, S; Ma, GM; Ni, LS; Penner, B; Shen, GX; Woo, V; Zhu, F, 2006) |
| " We investigated the influence of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension." | 9.12 | Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. ( Chenevard, R; Flammer, AJ; Gay, S; Hermann, F; Hürlimann, D; Lehmann, R; Lüscher, TF; Neidhart, M; Noll, G; Riesen, W; Ruschitzka, F; Schwegler, B; Sudano, I; Wiesli, P, 2007) |
| " Therefore, this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo-controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study." | 9.12 | Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Eijkelkamp, WB; Gleim, GW; Keane, WF; Parving, HH; Remuzzi, G; Shahinfar, S; Weir, MR; Zhang, Z, 2007) |
| " We hypothesized that treatment with losartan as compared to atenolol would improve insulin sensitivity through regression of peripheral vascular hypertrophy/rarefaction." | 9.11 | Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. ( Andersen, UB; Fossum, E; Gaboury, CL; Hjerkinn, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Nesbitt, SD; Olsen, MH; Phillips, RA; Wachtell, K, 2005) |
| "We explored the impact of baseline left ventricular hypertrophy (LVH) and losartan treatment on renal and cardiovascular (CV) events in 1,513 patients from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, which studied the effects of losartan on the progression of renal disease and/or death in patients with type 2 diabetes and nephropathy." | 9.11 | Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Boner, G; Brenner, BM; Cooper, ME; Crow, RS; de Zeeuw, D; Dickson, T; Kowey, PR; McCarroll, K; Parving, HH; Shahinfar, S, 2005) |
| "Both lercanidipine and losartan attenuate LDL oxidation in patients with type 2 diabetes mellitus and hypertension." | 9.10 | Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. ( Levi, Z; Rachmani, R; Ravid, M; Zadok, BS, 2002) |
| "Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study demonstrated the benefit of losartan in reducing renal outcomes in patients with type 2 diabetes and proteinuria." | 9.10 | Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. ( Ahmed, T; Brenner, BM; Dickson, TZ; Ramjit, D; Shahinfar, S; Smith, RD; Zhang, Z, 2002) |
| "To assess the antiproteinuric effects of losartan in normotensive patients with type 2 diabetes and microalbuminuria." | 9.10 | Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. ( Baggen, MG; Bootsma, AH; de Zeeuw, D; Lamberts, SW; Ouwendijk, RJ; Zandbergen, AA, 2003) |
| "We studied the efficacy of losartan (50 mg once daily for 12 weeks) on albuminuria, peripheral and autonomic neuropathy in 25 normotensive microalbuminuric type 2 diabetics who were asymptomatic for neuropathy." | 9.10 | Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normotensive microalbuminuric type 2 diabetics. ( Agarwal, SK; Anuradha, S; Babbar, R; Kubba, S; Prakash, A; Puri, V, 2003) |
| "The aim of the present study was to determine the effect of losartan on transforming growth factor-beta1 (TGF-beta1) plasma levels and urinary albumin excretion (UAE) in patients with type 2 diabetes mellitus, mild hypertension and microalbuminuria." | 9.09 | Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. ( Campistol, JM; Esmatjes, E; Flores, L; Iñigo, P; Lario, S; Ruilope, LM, 2001) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 8.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| " Losartan stabilized all of these parameters and hindered the progression of fibrosis, but it did not reverse the pre-existing fibrotic manifestations." | 7.81 | Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis. ( Arnoni, CP; Boim, MA; Maquigussa, E; Passos, CS; Pereira, LG, 2015) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 7.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "To assess the therapeutic effect of losartan on type 2 diabetes mellitus (DM2) with gas chromatography (GC)-based metabonomics." | 7.74 | [Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics]. ( Gao, P; Lu, X; Shi, XZ; Xu, GW; Yuan, KL, 2007) |
| " With the use of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study database as an example, the influence of baseline proteinuria on the primary composite endpoint, ESRD, and ESRD or death after adjusting for baseline proteinuria as a continuous covariate was examined." | 7.73 | Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Brenner, BM; de Zeeuw, D; Dickson, TZ; Gleim, GW; Keane, WF; Mogensen, CE; Ramjit, D; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005) |
| "Serum EC-SOD concentrations may be a sensitive biochemical marker of insulin resistance in patients with type 2 diabetes and hypertension and that losartan improves insulin sensitivity by increasing EC-SOD and adiponectin production and decreasing TNF-alpha production." | 7.73 | Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. ( Adachi, T; Fujinami, A; Fukui, M; Hara, H; Hasegawa, G; Kimura, F; Nakajima, Y; Nakamura, N; Obayashi, H; Ogata, M; Ohta, M; Park, H; Tamaki, S; Yoshikawa, T, 2006) |
| "We describe the reversal of losartan-induced oligohydramnios at 27 weeks of gestation with subsequent development of fetal thrombosis and possible mechanism of action for this extremely rare in utero complication." | 7.73 | In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis. ( Bakkum, JN; Brost, BC; Johansen, KL; Johnston, BW; Watson, WJ, 2006) |
| "The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol." | 7.72 | How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade? ( Dawson, A; Donnelly, LA; Morris, AD; Pringle, SD; Rana, BS; Struthers, AD, 2004) |
| "The specific inhibition of angiotensin II action at AT(1) receptors by losartan has been shown to decrease peripheral insulin resistance in type 2 diabetic patients and animal models." | 7.72 | Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats. ( Ouyang, JP; Wen, CY; Wu, K; Wu, Y; Zhao, DH; Zhou, YF, 2004) |
| "Essential hypertension has been extensively reported to cause endothelial dysfunction." | 6.82 | Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM, 2016) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 6.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 6.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| " The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study provided the opportunity to estimate costs associated with ESRD by baseline albuminuria from a United States perspective." | 6.21 | Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. ( Alexander, CM; Carides, GW; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2004) |
| "To compare the blood pressure (BP)-lowering efficacy of a chlorthalidone/amiloride combination pill with losartan, during initial management of JNC 7 Stage I hypertension in patients with type 2 diabetes mellitus." | 5.41 | Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension and diabetes mellitus: results from the PREVER-treatment randomized controlled trial. ( Afiune Neto, A; Alves, JG; Berwanger, O; Bortolotto, LA; Brandão, AA; Castro, I; Cesarino, JE; Chaves, H; Consolim-Colombo, FM; de Sousa, MR; Figueiredo Neto, JA; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gomes, MM; Gus, M; Jardim, PC; Moreira, LB; Nobre, F; Nóbrega, AC; Pereira E Silva, R; Poli-de-Figueiredo, CE; Scala, LCN; Schlatter, RP; Sobral Filho, DC; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2021) |
| "Proteinuria was diagnosed in 2003 (DPE 3." | 5.35 | [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008) |
| "Losartan was well tolerated and demonstrated significant anti-proteinuric effects in patients with T2DM with early nephropathy independent of hypertension, warranting further long-term large-scale studies to prove its usefulness as preventive therapy for diabetic nephropathy." | 5.34 | Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus. ( Agha, A; Anwar, E; Bashir, K, 2007) |
| "Hypertension often complicates type 2 diabetes mellitus, and angiotensin converting enzyme inhibitor treatment has been shown to improve insulin resistance in such cases." | 5.31 | Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats. ( Ebina, Y; Houchi, H; Ishizawa, K; Kishi, K; Minakuchi, K; Nakaya, Y; Takishita, E; Tamaki, T; Tsuchiya, K; Yoshizumi, M, 2001) |
| "Losartan treatment significantly decreased both AUC(glucose)and AUC(insulin)values." | 5.31 | Improvement in insulin sensitivity by losartan in non-insulin-dependent diabetic (NIDDM) rats. ( Goyal, RK; Murali, B, 2001) |
| "In this randomised, double-blind, placebo-controlled, crossover trial, we recruited adult patients with type 2 diabetes from six diabetology outpatient clinics in northern Italy, with 24 h albuminuria of more than 300 mg despite 100 mg per day losartan therapy, blood pressure of less than 140/90 mm Hg, serum creatinine concentration of less than 2 mg/dL, stable renal function on stable renin-angiotensin system inhibitor therapy with a fixed dose of losartan, parathyroid hormone concentration of 20 pg/mL to <110 pg/mL, serum calcium concentration of less than 9·5 mg/dL, and serum phosphate concentration of less than 5 mg/dL, who had been more than 80% compliant with placebo treatment during a 1 month placebo run-in." | 5.27 | Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. ( Abbate, M; Belviso, A; Bossi, AC; Carrara, F; de Borst, M; Diadei, O; Gaspari, F; Iliev, IP; Parvanova, A; Peraro, F; Perna, A; Podestà, MA; Remuzzi, G; Rubis, N; Ruggenenti, P; Ruggiero, B; Stucchi, N; Trevisan, R; Trillini, M, 2018) |
| "The aim of this study was to assess the antihypertensive efficacy and safety of aliskiren versus ramipril or losartan in hypertensive patients with type 2 diabetes mellitus, microalbuminuria and uncontrolled hypertension, despite the use of optimal conventional antihypertensive therapy." | 5.20 | Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria. ( Creazzo, M; Dalbeni, A; Dattilo, G; Imbalzano, E; Lizio, G; Mandraffino, G; Saitta, A; Sardo, MA; Scarpelli, M; Tomasello, C; Trapani, G, 2015) |
| "The purpose of this study was to compare the effects of benazepril and losartan on endothelial function and vascular stiffness, in patients with diabetes mellitus and hypertension." | 5.20 | Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A randomized controlled trial. ( Bedirian, R; Gismondi, RA; Ladeira, MC; Neves, MF; Oigman, W; Pozzobon, CR, 2015) |
| "Changes in systolic blood pressure (SBP), albuminuria, potassium, haemoglobin, cholesterol and uric acid after 6 months of losartan treatment were assessed in the RENAAL database." | 5.20 | The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. ( de Zeeuw, D; Lambers Heerspink, HJ; Parving, HH; Rossing, P; Schievink, B, 2015) |
| "The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus." | 5.20 | Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Dario Ragonesi, P; Derosa, G; Franzetti, I; Maffioli, P; Querci, F, 2015) |
| "The aim of this study was to evaluate the effects of lercanidipine or barnidipine on echocardiographic parameters, in hypertensive, type 2 diabetics with left ventricular hypertrophy." | 5.20 | Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. ( D'Angelo, A; Derosa, G; Franzetti, I; Maffioli, P; Mugellini, A; Pesce, RM; Querci, F, 2015) |
| "Patients with diabetes and hypertension with office systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 80 mmHg had their antihypertensive medications replaced by amlodipine during 6 weeks." | 5.20 | Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics. ( Bedirian, R; Gismondi, RA; Ladeira, MC; Neves, MF; Oigman, W; Pozzobon, CR, 2015) |
| "A total of 439 hypertensive patients with metabolic syndrome and/or diabetes mellitus were randomized to 2 groups: group 1--ramipril (ACE-I) or perindopril and group 2--losartan (ARB)." | 5.19 | Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study). ( Soucek, M; Spinar, J; Vitovec, J, 2014) |
| "Patients with a previous diagnosis of hypertension and type 2 diabetes mellitus were randomly divided into 2 groups and evaluated after 6 weeks of treatment with amlodipine (5 mg/day) or losartan (100 mg/day)." | 5.19 | Functional vascular study in hypertensive subjects with type 2 diabetes using losartan or amlodipine. ( Bedirian, R; Gismondi, RA; Ladeira, MC; Neves, MF; Oigman, W; Pozzobon, CR, 2014) |
| "In this post-hoc analysis of a randomized crossover study, 33 T2DM subjects with albuminuria received either 50 mg of losartan or 20 mg of quinapril (both 50% maximal dose) daily for 4 weeks with 4-week wash-out period in between." | 5.19 | Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients. ( Lim, SC; Liu, JJ; Subramaniam, T; Sum, CF, 2014) |
| " In multivariable Cox analyses, adjusting for randomized treatment, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum creatinine and glucose entered as standard covariates, and in-treatment non-HDL cholesterol, Cornell product left ventricular hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use as time-varying covariates, the lowest quartile of in-treatment HDL remained associated with a nearly 9-fold increased risk of new diabetes (hazard ratio 8." | 5.17 | In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM; Wiik, BP, 2013) |
| " Patients with type 2 diabetes and hypertension on maximal RAS blockade (n=70) were randomized to nebivolol or metoprolol succinate daily." | 5.17 | Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. ( Bakris, G; Briasoulis, A; Flynn, C; Kalaitzidis, R; Lazich, I; Oliva, R; Schlaffer, C, 2013) |
| "To compare the effects of losartan and amlodipine on myocardial structure and function in hypertensive patients with Type 2 diabetes and left ventricular hypertrophy." | 5.16 | Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. ( Corradi, L; Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2012) |
| " Telmisartan, one of the currently available angiotensin II type 1 receptor blockers (ARBs), has been shown to exert a more powerful proteinuria (albuminuria) reduction in patients with DN, but whether the prominent renoprotective effect of telmisartan is mediated through enhancing antioxidant defense capacity and reducing oxidative stress has not been fully elucidated." | 5.15 | Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. ( Fujishima, H; Fujita, H; Komatsu, K; Morii, T; Narita, T; Sakamoto, T; Takahashi, T; Yamada, Y, 2011) |
| "Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85-105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56)." | 5.14 | Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Wenzel, RR, 2009) |
| "To evaluate effects of 6-month therapy with losartan in combination with indapamide on a clinical course, immunological, metabolic parameters, left ventricular function, exercise tolerance and quality of life in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS)." | 5.14 | [Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus]. ( Bolotskaia, LA; Derbeneva, NV; Frants, MV; Kuznetsova, AV; Lukinov, AV; Maianskaia, SD; Shilov, SN; Stepacheva, TA; Tepliakov, AT; Vdovina, TV, 2009) |
| "A prospective, open label, parallel group and randomized study was conducted to see the effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients." | 5.14 | Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. ( Hoque, R; Iqbal, M; Rahman, MS, 2009) |
| "It is unclear whether serum uric acid (SUA) is associated with development of new-onset diabetes (NOD) in patients with hypertension and left ventricular hypertrophy (LVH)." | 5.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| "Aliskiren added to losartan reduced albuminuria and renal dysfunction and was well tolerated, except for hyperkalemia (stage 3), independent of baseline CKD stage in patients with type 2 diabetes, hypertension, and nephropathy." | 5.14 | Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. ( Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F; Rossing, P, 2010) |
| " We evaluated the renoprotective effects of dual blockade of the renin-angiotensin-aldosterone system by adding treatment with aliskiren, an oral direct renin inhibitor, to treatment with the maximal recommended dose of losartan (100 mg daily) and optimal antihypertensive therapy in patients who had hypertension and type 2 diabetes with nephropathy." | 5.13 | Aliskiren combined with losartan in type 2 diabetes and nephropathy. ( Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F, 2008) |
| "The ADHT (Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial) evaluated the efficacy and safety of adding amlodipine to the treatment regimen of patients with hypertension and diabetes who were already receiving either quinapril or losartan as monotherapy." | 5.13 | Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. ( Gregg, AM; Kloner, RA; Neutel, J; Roth, EM; Schwartz, B; Shi, H; Thakker, KM; Weinberger, MH; Weiss, R, 2008) |
| "The study demonstrated that the combination of manidipine and delapril is as effective as losartan and hydrochlorothiazide in treatment of hypertension in type 2 diabetes." | 5.13 | Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Triposkiadis, F; Wenzel, RR, 2008) |
| "In this study we evaluated the effect of a dual blockade with enalapril and losartan on the reduction of overt macroproteinuria and its potential mechanism(s) in hypertensive patients with type 2 diabetes." | 5.12 | Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. ( Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M, 2006) |
| "In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy." | 5.12 | Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007) |
| "Twenty-two type 2 DM patients with microalbuminuria were treated with 50-100 mg/day of Losartan for 6 months." | 5.12 | Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria. ( Berard, L; Hak, D; Khan, S; Ma, GM; Ni, LS; Penner, B; Shen, GX; Woo, V; Zhu, F, 2006) |
| " We investigated the influence of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension." | 5.12 | Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. ( Chenevard, R; Flammer, AJ; Gay, S; Hermann, F; Hürlimann, D; Lehmann, R; Lüscher, TF; Neidhart, M; Noll, G; Riesen, W; Ruschitzka, F; Schwegler, B; Sudano, I; Wiesli, P, 2007) |
| " Therefore, this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo-controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study." | 5.12 | Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Eijkelkamp, WB; Gleim, GW; Keane, WF; Parving, HH; Remuzzi, G; Shahinfar, S; Weir, MR; Zhang, Z, 2007) |
| "Forty-one ARB- and ACE inhibitor-naive T2DM subjects with albuminuria (>30 mg/g creatinine) were given either 50 mg of losartan (ARB) or 20 mg of quinapril (ACE inhibitor) (50% maximum dose) for 4 weeks, with a 4-week wash-out period in-between interventions in a crossover fashion." | 5.12 | Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study. ( Chua, CL; Goh, SK; Heng, BL; Koh, AF; Lim, SC; Subramaniam, T; Sum, CF, 2007) |
| "We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline or reduction in albuminuria." | 5.11 | Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, S; Zhang, Z, 2004) |
| " We hypothesized that treatment with losartan as compared to atenolol would improve insulin sensitivity through regression of peripheral vascular hypertrophy/rarefaction." | 5.11 | Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. ( Andersen, UB; Fossum, E; Gaboury, CL; Hjerkinn, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Nesbitt, SD; Olsen, MH; Phillips, RA; Wachtell, K, 2005) |
| "This post hoc analysis examined whether baseline proteinuria was predictive of cardiovascular outcomes, and whether losartan modifies the risk of cardiovascular outcomes in these patients given its renal-protective effects." | 5.11 | Losartan and end-organ protection--lessons from the RENAAL study. ( Brenner, BM; Dickson, TZ; Kowey, PR; Shahinfar, S; Zhang, Z, 2005) |
| "These results suggest that in type 2 diabetes with overt nephropathy, 24-h blood pressure regulation alone is inadequate to reduce macroalbuminuria and additional effects of losartan are crucial for antiproteinuric action." | 5.11 | Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. ( Ando, D; Hirawa, N; Tochikubo, O; Umemura, S; Yasuda, G, 2005) |
| "We explored the impact of baseline left ventricular hypertrophy (LVH) and losartan treatment on renal and cardiovascular (CV) events in 1,513 patients from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, which studied the effects of losartan on the progression of renal disease and/or death in patients with type 2 diabetes and nephropathy." | 5.11 | Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Boner, G; Brenner, BM; Cooper, ME; Crow, RS; de Zeeuw, D; Dickson, T; Kowey, PR; McCarroll, K; Parving, HH; Shahinfar, S, 2005) |
| "We sought to study the risk factors for heart failure (HF) and the relation between antihypertensive treatment with losartan and the first hospitalization for HF in patients with diabetes mellitus in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) and Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) studies." | 5.11 | Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. ( Brenner, BM; Carr, AA; Dahlöf, B; Devereux, RB; Edelman, JM; Ibsen, H; Kowey, PR; Lindholm, LH; Lyle, PA; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005) |
| "Both lercanidipine and losartan attenuate LDL oxidation in patients with type 2 diabetes mellitus and hypertension." | 5.10 | Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. ( Levi, Z; Rachmani, R; Ravid, M; Zadok, BS, 2002) |
| "Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study demonstrated the benefit of losartan in reducing renal outcomes in patients with type 2 diabetes and proteinuria." | 5.10 | Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. ( Ahmed, T; Brenner, BM; Dickson, TZ; Ramjit, D; Shahinfar, S; Smith, RD; Zhang, Z, 2002) |
| "To assess the antiproteinuric effects of losartan in normotensive patients with type 2 diabetes and microalbuminuria." | 5.10 | Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. ( Baggen, MG; Bootsma, AH; de Zeeuw, D; Lamberts, SW; Ouwendijk, RJ; Zandbergen, AA, 2003) |
| "We studied the efficacy of losartan (50 mg once daily for 12 weeks) on albuminuria, peripheral and autonomic neuropathy in 25 normotensive microalbuminuric type 2 diabetics who were asymptomatic for neuropathy." | 5.10 | Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normotensive microalbuminuric type 2 diabetics. ( Agarwal, SK; Anuradha, S; Babbar, R; Kubba, S; Prakash, A; Puri, V, 2003) |
| "5 mg of hydrochlorothiazide, in 90 type 2 diabetic patients with microalbuminuria and blood pressure > 130/85 mmHg, receiving losartan 50 mg as initial treatment during 4 weeks." | 5.10 | Losartan titration versus diuretic combination in type 2 diabetic patients. ( de Pablos-Velasco, PL; Esmatjes, JE; Fernandez-Vega, F; Lopez de la Torre, ML; Pazos Toral, F; Pozuelo, A; Ruilope, LM, 2002) |
| "Twenty-one subjects with hypertension and AER between 10 and 200 microg/min were randomized to receive either 50 mg losartan daily (n = 11) or placebo (n = 10)." | 5.10 | Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. ( Akdeniz, A; Cooper, ME; Gilbert, RE; Houlihan, CA; Jerums, G; Tsalamandris, C, 2002) |
| "The objectives of this study were to compare the effects of the angiotensin II receptor blocker, losartan, to those of the angiotensin-converting enzyme inhibitor, enalapril, on albuminuria and renal function in relationship to clinic and ambulatory blood pressure (ABP) in hypertensive type 2 diabetic subjects with early nephropathy." | 5.09 | Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. ( Bélanger, A; Godin, C; Hallé, JP; Lacourcière, Y; Marion, J; Ross, S; Wright, N, 2000) |
| "The aim of the present study was to determine the effect of losartan on transforming growth factor-beta1 (TGF-beta1) plasma levels and urinary albumin excretion (UAE) in patients with type 2 diabetes mellitus, mild hypertension and microalbuminuria." | 5.09 | Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. ( Campistol, JM; Esmatjes, E; Flores, L; Iñigo, P; Lario, S; Ruilope, LM, 2001) |
| "We compared the efficacy of treatment protocols with an angiotensin converting enzyme (ACE) inhibitor alone (enalapril, 5 mg) or angiotensin II (ATII) receptor blocker (losartan, 50 mg) or both enalapril plus losartan in patients with microalbuminuria in a prospective, randomized clinical trial." | 5.09 | Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. ( Gedik, O; Gürlek, A; Tütüncü, NB, 2001) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria." | 4.82 | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003) |
| " THC was administered via daily oral gavage with the lipid carrier polyenylphosphatidylcholine (PPC) as add-on therapy to losartan (angiotensin receptor blocker) to examine effects on kidney oxidative stress and fibrosis." | 4.31 | Tetrahydrocurcumin Add-On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury. ( Khazaali, M; Khazaeli, M; Lau, WL; Nunes, ACF; Prudente, J; Singh, B; Vaziri, ND; Zhao, Y, 2023) |
| "Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)." | 4.21 | ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022) |
| " Losartan stabilized all of these parameters and hindered the progression of fibrosis, but it did not reverse the pre-existing fibrotic manifestations." | 3.81 | Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis. ( Arnoni, CP; Boim, MA; Maquigussa, E; Passos, CS; Pereira, LG, 2015) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin II AT(1) receptor antagonist." | 3.80 | Losartan in diabetic nephropathy. ( Carswell, CI; Goa, KL, 2003) |
| " Patients were administered either losartan or placebo, each in addition to conventional antihypertensive therapy, with dosage adjustments as necessary to achieve a target blood pressure of less than 140/less than 90 mm Hg." | 3.80 | Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. ( Keane, WF; Lyle, PA, 2003) |
| " We hypothesized that insulin-induced relaxation and the associated proline-rich tyrosine kinase 2 (Pyk2)/Src/Akt pathway would be abnormal in aortas from the Goto-Kakizaki (GK) type 2 diabetic rat, which exhibits hyperglycemia/insulin resistance, and that losartan treatment of such rats (25 mg·kg(-1)·day(-1) for 2 wk) would correct these abnormalities." | 3.77 | Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats. ( Kamata, K; Kobayashi, T; Matsumoto, T; Nemoto, S; Taguchi, K, 2011) |
| "Aliskiren significantly attenuated albuminuria and glomerular mesangial matrix expansion in db/db mice, which was associated with the improvement of the increased glomerular transforming growth factor-beta and type IV collagen expressions, the increased macrophage infiltration, and the decreased glomerular nephrin expression of db/db mice." | 3.76 | Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E, 2010) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 3.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "To assess the therapeutic effect of losartan on type 2 diabetes mellitus (DM2) with gas chromatography (GC)-based metabonomics." | 3.74 | [Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics]. ( Gao, P; Lu, X; Shi, XZ; Xu, GW; Yuan, KL, 2007) |
| " With the use of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study database as an example, the influence of baseline proteinuria on the primary composite endpoint, ESRD, and ESRD or death after adjusting for baseline proteinuria as a continuous covariate was examined." | 3.73 | Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Brenner, BM; de Zeeuw, D; Dickson, TZ; Gleim, GW; Keane, WF; Mogensen, CE; Ramjit, D; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005) |
| "Serum EC-SOD concentrations may be a sensitive biochemical marker of insulin resistance in patients with type 2 diabetes and hypertension and that losartan improves insulin sensitivity by increasing EC-SOD and adiponectin production and decreasing TNF-alpha production." | 3.73 | Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. ( Adachi, T; Fujinami, A; Fukui, M; Hara, H; Hasegawa, G; Kimura, F; Nakajima, Y; Nakamura, N; Obayashi, H; Ogata, M; Ohta, M; Park, H; Tamaki, S; Yoshikawa, T, 2006) |
| "We describe the reversal of losartan-induced oligohydramnios at 27 weeks of gestation with subsequent development of fetal thrombosis and possible mechanism of action for this extremely rare in utero complication." | 3.73 | In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis. ( Bakkum, JN; Brost, BC; Johansen, KL; Johnston, BW; Watson, WJ, 2006) |
| "The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol." | 3.72 | How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade? ( Dawson, A; Donnelly, LA; Morris, AD; Pringle, SD; Rana, BS; Struthers, AD, 2004) |
| "The specific inhibition of angiotensin II action at AT(1) receptors by losartan has been shown to decrease peripheral insulin resistance in type 2 diabetic patients and animal models." | 3.72 | Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats. ( Ouyang, JP; Wen, CY; Wu, K; Wu, Y; Zhao, DH; Zhou, YF, 2004) |
| "Participants were American Indians with type 2 diabetes enrolled in a clinical trial of losartan versus placebo." | 2.90 | Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes. ( Boustany-Kari, CM; Esplin, CA; Guarnieri, P; Harder, JL; Hill, J; Kretzler, M; Looker, HC; Mauer, M; Nair, V; Najafian, B; Nelson, RG; Saulnier, PJ, 2019) |
| "Essential hypertension has been extensively reported to cause endothelial dysfunction." | 2.82 | Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM, 2016) |
| "2,628 adults with type 2 diabetes and nephropathy." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| "Treatment with losartan may preserve some features of kidney structure in American Indians with type 2 diabetes and microalbuminuria." | 2.78 | Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. ( Bennett, PH; Fufaa, G; Hanson, RL; Jones, LI; Knowler, WC; Lemley, KV; Lovato, T; Myers, BD; Nelson, RG; Weil, EJ; Yee, B, 2013) |
| "In patients with type 2 diabetes, by comparison, the mean percentage of podocyte detachment was significantly higher in macroalbuminuria (1." | 2.77 | Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. ( Blouch, K; Jones, LI; Lemley, KV; Lovato, T; Mason, CC; Myers, BD; Nelson, RG; Richardson, M; Weil, EJ; Yee, B, 2012) |
| "Losartan was an independent predictor for serum potassium ≥5." | 2.76 | Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Dobre, D; Grobbee, D; Heerspink, HJ; Miao, Y; Parving, HH; Shahinfar, S, 2011) |
| " The adverse effects included dry cough (seven [19." | 2.75 | Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. ( Lee, KO; Liew, CF; Lim, P; Mukherjee, JJ; Tan, F, 2010) |
| "Sixty-eight diabetic nephropathy patients with microalbuminuria were randomly allocated to 1 of 4 treatment groups: losartan 100 mg/day (group A), candesartan 12 mg/day (group B), olmesartan 40 mg/day (group C), or telmisartan 80 mg/day (group D)." | 2.75 | Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy. ( Fujiwara, N; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y, 2010) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 2.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "Fourteen type 2 diabetes patients were included." | 2.74 | Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients. ( Hesse, B; Kjaer, A; Kristoffersen, US; Parving, HH; Tarnow, L, 2009) |
| "This study was performed to ascertain whether losartan combined with pioglitazone is superior to losartan alone in delaying the progression of chronic renal failure in patients with type 2 diabetic nephropathy." | 2.73 | Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. ( Jin, HM; Pan, Y, 2007) |
| "Losartan treatment reduced renal outcomes in proteinuric patients with type 2 diabetes in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study." | 2.73 | ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Liu, N; Lunceford, J; Lyle, PA; Parving, HH; Remuzzi, G; Rossing, P; Shahinfar, S; Wong, PH, 2008) |
| "Losartan has been shown to protect the diabetic kidney, at least partly independent of changes in blood pressure." | 2.72 | The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. ( Baggen, MG; Boersma, E; Bootsma, AH; Janssen, JA; Lamberts, SW; Zandbergen, AA, 2006) |
| " We tested for effect modification by age of the effect of losartan on the incidence of the predefined end points (doubling of serum creatinine, end-stage renal disease [ESRD], or death) and the risk of adverse events." | 2.72 | Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. ( Avorn, J; Brenner, BM; Cooper, ME; Shahinfar, S; Winkelmayer, WC; Zhang, Z, 2006) |
| "Levels of proteinuria were reduced with losartan compared with placebo, with an overall losartan treatment effect of 37." | 2.72 | Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. ( Chan, JC; Cooper, ME; Keane, WF; Kurokawa, K; Shahinfar, S; Zhang, Z, 2006) |
| "The etiology of CKD was type 2 diabetes mellitus in 12 and glomerulonephritis in 4 patients." | 2.71 | Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. ( Agarwal, R, 2003) |
| "Treatment with losartan in patients with type 2 diabetes and nephropathy not only reduced the incidence of ESRD, but also resulted in substantial cost savings." | 2.71 | Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. ( Alexander, CM; Brenner, BM; Carides, GW; Cook, JR; Dasbach, EJ; Gerth, WC; Herman, WH; Keane, WF; Shahinfar, S, 2003) |
| "The reduction in the number of ESRD days over 4 years in patients treated with losartan significantly decreased costs associated with ESRD by 7,438 euros per patient (CI 95%: 3,029 euros - 11,847 euros, p=0." | 2.71 | An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. ( Durand Zaleski, I; Gaugris, S; Hannedouche, T; Passa, P; Rodier, M; Souchet, T, 2003) |
| "In the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, approximately 17% of patients were Asians." | 2.71 | Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. ( Brenner, BM; Chan, JC; Chua, CT; Cooper, ME; Dickson, TZ; Hille, D; Kurokawa, K; Lam, KS; Morad, Z; Shahinfar, S; So, WY; Wat, NM; Wong, KS; Zhang, Z, 2004) |
| "The Reduction of Endpoints in NIDDM [non-insulin-dependent diabetes mellitus] with the Angiotensin II Antagonist Losartan (RENAAL) study demonstrated the renoprotective effects of losartan in patients with nephropathy from type 2 diabetes." | 2.71 | Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. ( Burgess, ED; Carides, GW; Chabot, I; Gerth, WC; Marentette, MA, 2004) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD)." | 2.71 | Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Keane, WF; Mohanram, A; Shahinfar, S; Toto, RD; Zhang, Z, 2004) |
| "Diabetic nephropathy with ESRD for type 2 diabetes mellitus (DM) now has to be recognized as a growing public health problem." | 2.71 | The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study. ( Keusch, GW; Sandoz, MS; Szucs, TD, 2004) |
| "In proteinuric individuals with type 2 diabetes, losartan therapy reduced ESRD and hospitalizations for heart failure and was well tolerated at all levels of renal function." | 2.71 | Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. ( Brenner, BM; Carides, GW; de Zeeuw, D; Dimitrov, BD; Hille, DA; Perna, A; Remuzzi, G; Ruggenenti, P; Shahinfar, S, 2004) |
| "Treatment with losartan in patients with type 2 diabetic nephropathy not only reduced the incidence of ESRD among Asian patients, but resulted in direct medical cost savings in countries or regions representing Asia." | 2.71 | Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective. ( Burke, TA; Carides, GW; Chan, J; Choi, YJ; Han, DC; Hwang, SJ; Seng, WK; Teong, CC, 2005) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 2.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | 2.70 | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | 2.70 | [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001) |
| "Among the 1,281 patients with incident cancer and 5,104 controls, 333 (26." | 2.47 | Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. ( Chang, CH; Lai, MS; Lin, JW; Wu, LC, 2011) |
| "Diabetic kidney disease is characterized by persistent albuminuria (>300 mg/dl or >200 microg/min) that is confirmed on at least 2 occasions 3 to 6 months apart, with a progressive decline in the glomerular filtration rate (GFR), elevated arterial blood pressure, and an increased risk for cardiovascular morbidity and mortality." | 2.45 | Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. ( Bichu, P; Khan, A; Nistala, R; Sowers, JR; Whaley-Connell, A, 2009) |
| "The potential benefit for treatment of the metabolic syndrome, cardiovascular protection, and prevention of related end-organ complications could be of immense clinical value." | 2.43 | Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. ( Pershadsingh, HA, 2006) |
| "Diabetes (particularly type 2 diabetes) represents a global health problem of epidemic proportions." | 2.43 | Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. ( Burnier, M; Zanchi, A, 2006) |
| "The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study was conducted from 1996 to 2001." | 2.43 | Losartan: lessons learned from the RENAAL study. ( Brenner, BM; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2006) |
| "Proteinuria is a sign of established kidney damage and plays a direct pathogenic role in the progression of renal and cardiovascular disease." | 2.43 | Time to abandon microalbuminuria? ( Remuzzi, G; Ruggenenti, P, 2006) |
| "For patients with type 2 diabetes mellitus (T2DM) and hypertension, an AII receptor blocker (AIIRB) is recommended as the first drug that should be used." | 2.42 | Advances in the treatment of diabetic renal disease: focus on losartan. ( Rayner, B, 2004) |
| "The earliest marker of incipient diabetic nephropathy is the transition of normoalbuminuria to microalbuminuria at an albumin excretion rate of 20 microg/min." | 2.42 | Losartan in diabetic nephropathy. ( Perico, N; Remuzzi, G; Ruggenenti, P, 2004) |
| "Recently, the Reduction of Endpoints in NIDDM (non-insulin-dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan (RENAAL) trial provided sufficient data to conclude that the blockade of the All AT1 receptor with losartan confers renoprotection in patients with DM-2 and nephropathy." | 2.41 | The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. ( Ribeiro, AB; Zanella, MT, 2002) |
| "In patients with diabetic kidney disease (DKD), the estimated glomerular filtration rate (eGFR) or creatinine clearance rate (Ccr) is always used as an index of decline in renal function." | 1.91 | Unilateral nephrectomized SHR/NDmcr-cp rat shows a progressive decline of glomerular filtration with tubular interstitial lesions. ( Fukui, K; Inagaki, K; Maekawa, M; Miyajima, K; Ohta, T; Shinozaki, Y; Toyoda, K; Uno, K; Yoshiuchi, H, 2023) |
| " In addition, the nephrectomized db /db mice from 10 weeks to 42 weeks were used to assess the efficacy of long-term administration of the angiotensin-II-receptor antagonist losartan." | 1.72 | Pathophysiological analysis of uninephrectomized db/db mice as a model of severe diabetic kidney disease. ( Kitamoto, M; Konishi, N; Maekawa, M; Maekawa, T; Nakagawa, T; Ohta, T; Sasase, T; Takagi, K; Takeuchi, S; Toyoda, K; Yamada, T, 2022) |
| "Losartan treatment alleviated some of the T2DM- induced metabolic complications, abolished the T2DM-induced hypo activity, and normalized the corticosterone level, carbonylated proteins in brain, nociception and memory." | 1.56 | Protective effects of losartan on some type 2 diabetes mellitus-induced complications in Wistar and spontaneously hypertensive rats. ( Grozdanov, P; Kostadinova, N; Krumova, E; Mitreva-Staleva, J; Pechlivanova, D; Stoynev, A, 2020) |
| "Podocyte loss and proteinuria are both key features of human diabetic nephropathy (DN)." | 1.56 | Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy. ( Alpers, CE; Hudkins, KL; Steegh, F; Wietecha, TA, 2020) |
| "Type 2 diabetes mellitus is a complex metabolic disorder requiring polypharmacology approaches for effective treatment." | 1.51 | Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators. ( Babkov, DA; Babkova, VA; Borisov, AV; Borodkin, GS; Brigadirova, AA; Kolodina, AA; Litvinov, RA; Morkovnik, AS; Sochnev, VS; Sokolova, EV; Spasov, AA; Zhukowskaya, ON, 2019) |
| "We studied the effect of apelin treatment on obesity-induced type 2 diabetes mellitus (T2DM) and possible interaction between apelin/APJ system and renin-angiotensin system (RAS)." | 1.51 | Interactive effects of apelin, renin-angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino rats. ( Ahmed, MM; Kamar, SS; Mahmoud, MM; Rashed, L; Sabry, MM; Shoukry, HS, 2019) |
| "Treatment with losartan reduced urinary protein excretion and blood lipids (triglyceride and cholesterol) dose-dependently in both studies." | 1.48 | Losartan improves renal function and pathology in obese ZSF-1 rats. ( Donnelly-Roberts, D; Gopalakrishnan, M; Leys, L; McGaraughty, S; Namovic, M; Nikkel, A; Su, Z; Widomski, D, 2018) |
| "Losartan treatment decreased wall thickness, wall-to-lumen ratio, and coronary arteriole cell number in db/db mice." | 1.43 | The angiotensin receptor blocker losartan reduces coronary arteriole remodeling in type 2 diabetic mice. ( Cismowski, MJ; Galantowicz, ML; Husarek, KE; Katz, PS; Lucchesi, PA; Trask, AJ, 2016) |
| "Data from patients with type 2 diabetes and microalbuminuria (n = 49) treated with irbesartan 300 mg/day were used for discovery." | 1.43 | Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus. ( Andersen, S; Dallmann, G; Heerspink, HJ; Heinzel, A; Mayer, B; Parving, HH; Pena, MJ; Rossing, K; Rossing, P, 2016) |
| "BACKGROUND Diabetic nephropathy (DN) is the most lethal diabetic microvascular complication; it is a major cause of renal failure, and an increasingly globally prominent healthcare problem." | 1.43 | Inhibiting MicroRNA-503 and MicroRNA-181d with Losartan Ameliorates Diabetic Nephropathy in KKAy Mice. ( Fan, Q; Jiang, Y; Liu, X; Wang, L; Yang, G; Zhang, C; Zhu, X, 2016) |
| "Losartan attenuated key parameters of diabetic nephropathy and gene expression, and reversed some but not all the epigenetic changes in db/db mice." | 1.40 | Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. ( Alpers, CE; Bomsztyk, K; Lanting, L; Mar, D; Natarajan, R; Reddy, MA; Sumanth, P; Wang, M; Yuan, H, 2014) |
| "Bilirubin was inversely associated with the renal end point in RENAAL independent of age, sex, race, BMI, smoking, total cholesterol, diastolic blood pressure, HbA1c, treatment, estimated glomerular filtration rate, albumin-to-creatinine ratio, and AST." | 1.40 | Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. ( Bakker, SJ; Cooper, ME; de Zeeuw, D; Deetman, PE; Lambers Heerspink, HJ; Lewis, JB; Navis, G; Riphagen, IJ, 2014) |
| "A non-obese type 2 diabetes model, the spontaneously diabetic Torii (SDT) rat, is of increasing preclinical interest because of its pathophysiological similarities to human type 2 diabetic complications including diabetic nephropathy." | 1.40 | Automated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartan. ( Fujitaka, K; Fukunari, A; Hirohashi, Y; Iguchi, T; Kakimoto, T; Kato, T; Kawai, M; Nishio, M; Okada, K; Relator, R; Utsumi, H, 2014) |
| "Diabetic nephropathy is a major cause of end-stage kidney disease, and overactivity of the endocannabinoid/cannabinoid 1 receptor (CB1R) system contributes to diabetes and its complications." | 1.40 | Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy. ( Cinar, R; Earley, BJ; Godlewski, G; Jourdan, T; Ju, C; Kunos, G; Liu, J; Liu, Z; Pacher, P; Rosenberg, AZ; Szanda, G; Tam, J, 2014) |
| "Obesity is often associated with chronic inflammatory state which contributes to the development of insulin resistance (IR) and type 2 diabetes mellitus (T2DM)." | 1.39 | Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats. ( El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A, 2013) |
| "Cotreatment with GW9662, a peroxisome proliferator-activated receptor-γ antagonist, interfered with these protective effects of telmisartan against cognitive function." | 1.38 | Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. ( Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Shudou, M; Tsukuda, K, 2012) |
| "To test this strategy in a model of type 2 diabetes, we treated 2-month-old diabetic Lprdb/db mice with losartan, paricalcitol, or a combination of losartan and paricalcitol for 3 months." | 1.36 | Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. ( Chang, A; Deb, DK; Kong, J; Li, YC; Ning, G; Shi, H; Sun, T; Wong, KE; Zhang, Y; Zhang, Z, 2010) |
| "It is well known that type 2 diabetes mellitus is frequently associated with vascular dysfunction and an elevated systemic blood pressure, yet the underlying mechanisms are not completely understood." | 1.36 | Mechanisms underlying the losartan treatment-induced improvement in the endothelial dysfunction seen in mesenteric arteries from type 2 diabetic rats. ( Ishida, K; Kamata, K; Kobayashi, T; Matsumoto, T; Nakayama, N; Taguchi, K, 2010) |
| "Proteinuria was diagnosed in 2003 (DPE 3." | 1.35 | [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008) |
| " This enhancement was improved by the chronic administration of the angiotensin II type I receptor (AT(1)-receptor) antagonist losartan (25 mg kg(-1), p." | 1.35 | Chronic treatment with losartan (angiotensin II type 1 receptor antagonist) normalizes enhanced acetylcholine-induced coronary vasoconstriction in isolated perfused hearts of type 2 diabetic OLETF rats. ( Kamata, K; Kobayashi, T; Matsumoto, T; Ozawa, Y; Taguchi, K, 2009) |
| "Losartan was well tolerated and demonstrated significant anti-proteinuric effects in patients with T2DM with early nephropathy independent of hypertension, warranting further long-term large-scale studies to prove its usefulness as preventive therapy for diabetic nephropathy." | 1.34 | Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus. ( Agha, A; Anwar, E; Bashir, K, 2007) |
| "Oral losartan treatment delayed the onset of diabetes, and reduced hyperglycemia and glucose intolerance in db/db mice, but did not affect the insulin sensitivity of peripheral tissues." | 1.33 | Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. ( Carlsson, PO; Chu, KY; Lau, T; Leung, PS, 2006) |
| "Type 2 diabetes is becoming the leading cause of end-stage renal disease (ESRD) worldwide." | 1.33 | Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. ( Brenner, BM; Chan, J; de Zeeuw, D; Kurokawa, K; Lash, JP; Ramjit, D; Remuzzi, G; Ribeiro, AB; Shahinfar, S; Zhang, Z, 2006) |
| "Treatment with losartan plus CT in patients with type 2 diabetes and nephropathy reduced the within-trial incidence of ESRD and is projected to result in lifetime reductions in ESRD and associated costs, and increased survival, versus placebo." | 1.33 | The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. ( Alexander, CM; Brenner, BM; Carides, GW; Dasbach, EJ; Gerth, WC; Herman, WH; Keane, WF; Shahinfar, S, 2006) |
| "Losartan was administered at 3 and 10 mg/kg/day and enalapril at 3 mg/kg/day for 14 weeks in the drinking water." | 1.32 | Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice. ( Kemi, M; Matsumoto, H; Nishikibe, M; Ohta, H; Sasaki, M; Taguchi, K; Uehara, S, 2004) |
| "Treatment with losartan not only reduced the incidence of ESRD, but also can result in substantial cost savings in the European Union." | 1.31 | Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. ( Brenner, B; Carides, GW; Gerth, WC; Hannedouche, T; Martinez-Castelao, A; Remuzzi, G; Shahinfar, S; Viberti, G, 2002) |
| "Hypertension often complicates type 2 diabetes mellitus, and angiotensin converting enzyme inhibitor treatment has been shown to improve insulin resistance in such cases." | 1.31 | Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats. ( Ebina, Y; Houchi, H; Ishizawa, K; Kishi, K; Minakuchi, K; Nakaya, Y; Takishita, E; Tamaki, T; Tsuchiya, K; Yoshizumi, M, 2001) |
| "Losartan treatment significantly decreased both AUC(glucose)and AUC(insulin)values." | 1.31 | Improvement in insulin sensitivity by losartan in non-insulin-dependent diabetic (NIDDM) rats. ( Goyal, RK; Murali, B, 2001) |
| "Patients with Type 2 diabetes and nephropathy should receive either an AT(1) antagonist or the angiotensin converting enzyme inhibitor ramipril to ensure renoprotection." | 1.31 | Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy. ( Doggrell, SA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (1.15) | 18.2507 |
| 2000's | 161 (61.45) | 29.6817 |
| 2010's | 90 (34.35) | 24.3611 |
| 2020's | 8 (3.05) | 2.80 |
| Authors | Studies |
|---|---|
| Babkov, DA | 1 |
| Zhukowskaya, ON | 1 |
| Borisov, AV | 1 |
| Babkova, VA | 1 |
| Sokolova, EV | 1 |
| Brigadirova, AA | 1 |
| Litvinov, RA | 1 |
| Kolodina, AA | 1 |
| Morkovnik, AS | 1 |
| Sochnev, VS | 1 |
| Borodkin, GS | 1 |
| Spasov, AA | 1 |
| Maekawa, M | 2 |
| Maekawa, T | 1 |
| Sasase, T | 1 |
| Takagi, K | 1 |
| Takeuchi, S | 1 |
| Kitamoto, M | 1 |
| Nakagawa, T | 2 |
| Toyoda, K | 2 |
| Konishi, N | 1 |
| Ohta, T | 2 |
| Yamada, T | 1 |
| Khazaeli, M | 1 |
| Nunes, ACF | 1 |
| Zhao, Y | 3 |
| Khazaali, M | 1 |
| Prudente, J | 1 |
| Vaziri, ND | 2 |
| Singh, B | 1 |
| Lau, WL | 1 |
| Shinozaki, Y | 1 |
| Fukui, K | 1 |
| Yoshiuchi, H | 1 |
| Inagaki, K | 1 |
| Uno, K | 1 |
| Miyajima, K | 1 |
| Pechlivanova, D | 1 |
| Krumova, E | 1 |
| Kostadinova, N | 1 |
| Mitreva-Staleva, J | 1 |
| Grozdanov, P | 1 |
| Stoynev, A | 1 |
| Hudkins, KL | 1 |
| Wietecha, TA | 1 |
| Steegh, F | 1 |
| Alpers, CE | 2 |
| Nese, M | 1 |
| Riboli, G | 1 |
| Brighetti, G | 1 |
| Sassi, V | 1 |
| Camela, E | 1 |
| Caselli, G | 1 |
| Sassaroli, S | 1 |
| Borlimi, R | 1 |
| Aucoin, M | 1 |
| Cooley, K | 1 |
| Saunders, PR | 1 |
| Carè, J | 1 |
| Anheyer, D | 1 |
| Medina, DN | 1 |
| Cardozo, V | 1 |
| Remy, D | 1 |
| Hannan, N | 1 |
| Garber, A | 1 |
| Velayos, M | 1 |
| Muñoz-Serrano, AJ | 1 |
| Estefanía-Fernández, K | 1 |
| Sarmiento Caldas, MC | 1 |
| Moratilla Lapeña, L | 1 |
| López-Santamaría, M | 1 |
| López-Gutiérrez, JC | 1 |
| Li, J | 1 |
| Zhang, J | 1 |
| Shen, S | 1 |
| Zhang, B | 2 |
| Yu, WW | 1 |
| Toyoda, H | 1 |
| Huang, DQ | 1 |
| Le, MH | 1 |
| Nguyen, MH | 1 |
| Huang, R | 1 |
| Zhu, L | 1 |
| Wang, J | 6 |
| Xue, L | 1 |
| Liu, L | 3 |
| Yan, X | 2 |
| Huang, S | 1 |
| Li, Y | 6 |
| Xu, T | 1 |
| Li, C | 2 |
| Ji, F | 1 |
| Ming, F | 1 |
| Cheng, J | 1 |
| Wang, Y | 3 |
| Zhao, H | 1 |
| Hong, S | 1 |
| Chen, K | 2 |
| Zhao, XA | 1 |
| Zou, L | 1 |
| Sang, D | 1 |
| Shao, H | 1 |
| Guan, X | 1 |
| Chen, X | 2 |
| Chen, Y | 4 |
| Wei, J | 1 |
| Zhu, C | 1 |
| Wu, C | 1 |
| Moore, HB | 1 |
| Barrett, CD | 1 |
| Moore, EE | 1 |
| Jhunjhunwala, R | 1 |
| McIntyre, RC | 1 |
| Moore, PK | 1 |
| Hajizadeh, N | 1 |
| Talmor, DS | 1 |
| Sauaia, A | 1 |
| Yaffe, MB | 1 |
| Liu, C | 3 |
| Lin, Y | 1 |
| Dong, Y | 1 |
| Wu, Y | 3 |
| Bao, Y | 1 |
| Yan, H | 2 |
| Ma, J | 1 |
| Fernández-Cuadros, ME | 1 |
| Albaladejo-Florín, MJ | 1 |
| Álava-Rabasa, S | 1 |
| Usandizaga-Elio, I | 1 |
| Martinez-Quintanilla Jimenez, D | 1 |
| Peña-Lora, D | 1 |
| Neira-Borrajo, I | 1 |
| López-Muñoz, MJ | 1 |
| Rodríguez-de-Cía, J | 1 |
| Pérez-Moro, OS | 1 |
| Abdallah, M | 1 |
| Alsaleh, H | 1 |
| Baradwan, A | 1 |
| Alfawares, R | 1 |
| Alobaid, A | 1 |
| Rasheed, A | 1 |
| Soliman, I | 1 |
| Wendel Garcia, PD | 1 |
| Fumeaux, T | 1 |
| Guerci, P | 1 |
| Heuberger, DM | 1 |
| Montomoli, J | 2 |
| Roche-Campo, F | 1 |
| Schuepbach, RA | 1 |
| Hilty, MP | 1 |
| Poloni, TE | 1 |
| Carlos, AF | 1 |
| Cairati, M | 1 |
| Cutaia, C | 1 |
| Medici, V | 1 |
| Marelli, E | 1 |
| Ferrari, D | 1 |
| Galli, A | 1 |
| Bognetti, P | 1 |
| Davin, A | 1 |
| Cirrincione, A | 1 |
| Ceretti, A | 1 |
| Cereda, C | 1 |
| Ceroni, M | 1 |
| Tronconi, L | 1 |
| Vitali, S | 1 |
| Guaita, A | 1 |
| Leeds, JS | 1 |
| Raviprakash, V | 1 |
| Jacques, T | 1 |
| Scanlon, N | 1 |
| Cundall, J | 1 |
| Leeds, CM | 1 |
| Riva, A | 1 |
| Gray, EH | 1 |
| Azarian, S | 1 |
| Zamalloa, A | 1 |
| McPhail, MJW | 1 |
| Vincent, RP | 1 |
| Williams, R | 1 |
| Chokshi, S | 1 |
| Patel, VC | 1 |
| Edwards, LA | 1 |
| Alqarawi, W | 1 |
| Birnie, DH | 1 |
| Golian, M | 1 |
| Nair, GM | 1 |
| Nery, PB | 1 |
| Klein, A | 1 |
| Davis, DR | 1 |
| Sadek, MM | 1 |
| Neilipovitz, D | 1 |
| Johnson, CB | 1 |
| Green, MS | 1 |
| Redpath, C | 1 |
| Miller, DC | 1 |
| Beamer, P | 1 |
| Billheimer, D | 1 |
| Subbian, V | 1 |
| Sorooshian, A | 1 |
| Campbell, BS | 1 |
| Mosier, JM | 1 |
| Novaretti, JV | 1 |
| Astur, DC | 1 |
| Cavalcante, ELB | 1 |
| Kaleka, CC | 1 |
| Amaro, JT | 1 |
| Cohen, M | 1 |
| Huang, W | 1 |
| Li, T | 1 |
| Ling, Y | 1 |
| Qian, ZP | 1 |
| Zhang, YY | 2 |
| Huang, D | 1 |
| Xu, SB | 1 |
| Liu, XH | 1 |
| Xia, L | 1 |
| Yang, Y | 3 |
| Lu, SH | 1 |
| Lu, HZ | 1 |
| Zhang, R | 2 |
| Ma, JX | 1 |
| Tang, S | 1 |
| Li, CM | 1 |
| Wan, J | 1 |
| Wang, JF | 1 |
| Ma, JQ | 1 |
| Luo, JJ | 1 |
| Chen, HY | 2 |
| Mi, SL | 1 |
| Chen, SY | 1 |
| Su, YG | 1 |
| Ge, JB | 1 |
| Milheiro, SA | 1 |
| Gonçalves, J | 1 |
| Lopes, RMRM | 1 |
| Madureira, M | 1 |
| Lobo, L | 1 |
| Lopes, A | 1 |
| Nogueira, F | 1 |
| Fontinha, D | 1 |
| Prudêncio, M | 1 |
| M Piedade, MF | 1 |
| Pinto, SN | 1 |
| Florindo, PR | 1 |
| Moreira, R | 1 |
| Castillo-Lora, J | 1 |
| Delley, MF | 1 |
| Laga, SM | 1 |
| Mayer, JM | 1 |
| Sutjarit, N | 1 |
| Thongon, N | 1 |
| Weerachayaphorn, J | 1 |
| Piyachaturawat, P | 1 |
| Suksamrarn, A | 1 |
| Suksen, K | 1 |
| Papachristou, DJ | 1 |
| Blair, HC | 1 |
| Hu, Y | 1 |
| Shen, P | 1 |
| Zeng, N | 1 |
| Wang, L | 4 |
| Yan, D | 1 |
| Cui, L | 1 |
| Yang, K | 2 |
| Zhai, C | 1 |
| Yang, M | 1 |
| Lao, X | 1 |
| Sun, J | 1 |
| Ma, N | 1 |
| Wang, S | 1 |
| Ye, W | 1 |
| Guo, P | 1 |
| Rahimi, S | 1 |
| Singh, MP | 1 |
| Gupta, J | 1 |
| Nakanishi, I | 1 |
| Ohkubo, K | 1 |
| Shoji, Y | 1 |
| Fujitaka, Y | 1 |
| Shimoda, K | 1 |
| Matsumoto, KI | 1 |
| Fukuhara, K | 1 |
| Hamada, H | 1 |
| van der Boom, T | 1 |
| Gruppen, EG | 1 |
| Lefrandt, JD | 1 |
| Connelly, MA | 1 |
| Links, TP | 1 |
| Dullaart, RPF | 1 |
| Berry, JD | 1 |
| Bedlack, R | 1 |
| Mathews, D | 1 |
| Agnese, W | 1 |
| Apple, S | 1 |
| Meloncelli, S | 1 |
| Divizia, M | 1 |
| Germani, G | 1 |
| Adefegha, SA | 1 |
| Bottari, NB | 1 |
| Leal, DB | 1 |
| de Andrade, CM | 1 |
| Schetinger, MR | 1 |
| Martínez-Velasco, A | 1 |
| Perez-Ortiz, AC | 1 |
| Antonio-Aguirre, B | 1 |
| Martínez-Villaseñor, L | 1 |
| Lira-Romero, E | 1 |
| Palacio-Pastrana, C | 1 |
| Zenteno, JC | 1 |
| Ramirez, I | 1 |
| Zepeda-Palacio, C | 1 |
| Mendoza-Velásquez, C | 1 |
| Camacho-Ordóñez, A | 1 |
| Ortiz Bibriesca, DM | 1 |
| Estrada-Mena, FJ | 1 |
| Martin, BL | 1 |
| Thompson, LC | 1 |
| Kim, YH | 2 |
| Snow, SJ | 1 |
| Schladweiler, MC | 1 |
| Phillips, P | 1 |
| Harmon, M | 1 |
| King, C | 1 |
| Richards, J | 1 |
| George, I | 1 |
| Haykal-Coates, N | 1 |
| Gilmour, MI | 1 |
| Kodavanti, UP | 1 |
| Hazari, MS | 1 |
| Farraj, AK | 1 |
| Shen, Z | 1 |
| Zou, Y | 1 |
| Gao, K | 1 |
| Lazar, S | 1 |
| Wurtzel, JGT | 1 |
| Ma, P | 1 |
| Goldfinger, LE | 1 |
| Vukelic, M | 1 |
| Laloo, A | 1 |
| Kyttaris, VC | 1 |
| Chen, R | 1 |
| Chen, J | 2 |
| Xun, J | 1 |
| Hu, Z | 1 |
| Huang, Q | 2 |
| Steinhart, C | 1 |
| Shen, Y | 1 |
| Lu, H | 2 |
| Mansuri, A | 1 |
| Lokhande, K | 1 |
| Kore, S | 1 |
| Gaikwad, S | 1 |
| Nawani, N | 1 |
| Swamy, KV | 1 |
| Junnarkar, M | 1 |
| Pawar, S | 1 |
| Shaheen, MY | 1 |
| Basudan, AM | 1 |
| Niazy, AA | 1 |
| van den Beucken, JJJP | 1 |
| Jansen, JA | 1 |
| Alghamdi, HS | 1 |
| Gao, Q | 2 |
| Guo, X | 1 |
| Cao, Y | 1 |
| Jia, X | 1 |
| Xu, S | 1 |
| Lu, C | 2 |
| Zhu, H | 2 |
| Melku, M | 1 |
| Abebe, G | 1 |
| Teketel, A | 1 |
| Asrie, F | 1 |
| Yalew, A | 1 |
| Biadgo, B | 1 |
| Kassa, E | 1 |
| Damtie, D | 1 |
| Anlay, DZ | 1 |
| Ahmed, MFE | 1 |
| Ramadan, H | 1 |
| Seinige, D | 1 |
| Kehrenberg, C | 1 |
| Abd El-Wahab, A | 1 |
| Volkmann, N | 1 |
| Kemper, N | 1 |
| Schulz, J | 1 |
| Hu, MY | 1 |
| Wu, YN | 1 |
| McEvoy, MP | 1 |
| Wang, YF | 1 |
| Cong, WL | 1 |
| Liu, LP | 1 |
| Li, XX | 1 |
| Zhou, CL | 1 |
| Chen, WM | 1 |
| Wei, KL | 1 |
| Tung, SY | 1 |
| Shen, CH | 1 |
| Chang, TS | 1 |
| Yen, CW | 1 |
| Hsieh, YY | 1 |
| Chiu, WN | 1 |
| Hu, JH | 1 |
| Lu, SN | 1 |
| Hung, CH | 1 |
| Alakavuklar, MA | 1 |
| Fuqua, C | 1 |
| Luo, KL | 1 |
| Underwood, RS | 1 |
| Greenwald, I | 1 |
| Elashiry, MM | 1 |
| Elashiry, M | 1 |
| Zeitoun, R | 1 |
| Elsayed, R | 1 |
| Tian, F | 1 |
| Saber, SE | 1 |
| Elashry, SH | 1 |
| Tay, FR | 1 |
| Cutler, CW | 1 |
| O'Dowd, A | 1 |
| Maciel, M | 1 |
| Poole, ST | 1 |
| Jobling, MG | 1 |
| Rollenhagen, JE | 1 |
| Woods, CM | 1 |
| Sincock, SA | 1 |
| McVeigh, AL | 1 |
| Gregory, MJ | 1 |
| Maves, RC | 1 |
| Prouty, MG | 1 |
| Holmes, RK | 1 |
| Savarino, SJ | 1 |
| Mor, MK | 1 |
| Palevsky, PM | 2 |
| Kaufman, JS | 1 |
| Thiessen Philbrook, H | 1 |
| Weisbord, SD | 1 |
| Parikh, CR | 1 |
| John, CM | 1 |
| Phillips, NJ | 1 |
| Jarvis, GA | 1 |
| Zhu, Y | 1 |
| Kilburn, S | 1 |
| Kapoor, M | 1 |
| Chaturvedi, S | 1 |
| Shaw, KJ | 1 |
| Chaturvedi, V | 1 |
| Kong, X | 1 |
| Zhang, T | 1 |
| Xiao, H | 1 |
| Feng, X | 1 |
| Tu, H | 1 |
| Feng, J | 1 |
| Sabet, M | 1 |
| Tarazi, Z | 1 |
| Griffith, DC | 1 |
| Nguyen, F | 1 |
| Guan, P | 1 |
| Guerrero, DT | 1 |
| Kolla, V | 1 |
| Naraparaju, K | 1 |
| Perry, LM | 1 |
| Soberman, D | 1 |
| Pressly, BB | 1 |
| Alferiev, IS | 1 |
| Chorny, M | 1 |
| Brodeur, GM | 1 |
| Gao, X | 2 |
| Cheng, YH | 1 |
| Enten, GA | 1 |
| DeSantis, AJ | 1 |
| Gaponenko, V | 1 |
| Majetschak, M | 1 |
| Kim, DY | 1 |
| Choi, MJ | 1 |
| Ko, TK | 1 |
| Lee, NH | 1 |
| Kim, OH | 1 |
| Cheon, HG | 1 |
| Cai, H | 1 |
| Yip, V | 1 |
| Lee, MV | 1 |
| Wong, S | 1 |
| Saad, O | 1 |
| Ma, S | 1 |
| Ljumanovic, N | 1 |
| Khojasteh, SC | 1 |
| Kamath, AV | 1 |
| Shen, BQ | 1 |
| Cuypers, ML | 1 |
| Chanteux, H | 1 |
| Gillent, E | 1 |
| Bonnaillie, P | 1 |
| Saunders, K | 1 |
| Beckers, C | 1 |
| Delatour, C | 1 |
| Dell'Aiera, S | 1 |
| Ungell, AL | 1 |
| Nicolaï, J | 1 |
| Knapp, AK | 1 |
| Chen, A | 1 |
| Griffin-Nolan, RJ | 1 |
| Baur, LE | 1 |
| Carroll, CJW | 1 |
| Gray, JE | 1 |
| Hoffman, AM | 1 |
| Li, X | 4 |
| Post, AK | 1 |
| Slette, IJ | 1 |
| Collins, SL | 1 |
| Luo, Y | 1 |
| Smith, MD | 1 |
| Temitayo, GI | 1 |
| Olawande, B | 1 |
| Emmanuel, YO | 1 |
| Timothy, AT | 1 |
| Kehinde, O | 1 |
| Susan, LF | 1 |
| Ezra, L | 1 |
| Joseph, OO | 1 |
| Lev, S | 1 |
| Desmarini, D | 1 |
| Liuwantara, D | 1 |
| Sorrell, TC | 1 |
| Hawthorne, WJ | 1 |
| Djordjevic, JT | 1 |
| Verso, MG | 1 |
| Costantino, C | 1 |
| Marrella, A | 1 |
| Immordino, P | 1 |
| Vitale, F | 1 |
| Amodio, E | 1 |
| Wang, YD | 1 |
| Yao, WL | 1 |
| Xin, ZM | 1 |
| Han, TT | 1 |
| Wang, ZG | 1 |
| Chen, L | 1 |
| Cai, C | 1 |
| Zhang, Y | 5 |
| Ba, D | 1 |
| Wen, S | 1 |
| Tian, Q | 1 |
| Lv, W | 1 |
| Cheng, G | 1 |
| Li, N | 1 |
| Yue, XY | 1 |
| Chu, WJ | 1 |
| Chen, Q | 1 |
| Choi, ES | 1 |
| Zhao, X | 3 |
| Zhou, HD | 1 |
| Sun, XF | 1 |
| Sharma, S | 2 |
| Chhoker, S | 1 |
| Xie, C | 1 |
| Ong, EWY | 1 |
| Tan, ZK | 1 |
| Evans, S | 1 |
| Weinheimer, CJ | 1 |
| Kovacs, A | 1 |
| Williams, JW | 1 |
| Randolph, GJ | 1 |
| Jiang, W | 1 |
| Barger, PM | 1 |
| Mann, DL | 2 |
| Liu, J | 3 |
| Huang, Y | 1 |
| Kong, L | 1 |
| Yu, X | 1 |
| Feng, B | 1 |
| Liu, D | 1 |
| Zhao, B | 1 |
| Mendes, GC | 1 |
| Yuan, P | 1 |
| Ge, D | 1 |
| Wang, WM | 1 |
| Fontes, EPB | 1 |
| Li, P | 1 |
| Shan, L | 1 |
| He, P | 1 |
| Katoh, T | 1 |
| Sengoku, T | 1 |
| Hirata, K | 1 |
| Ogata, K | 1 |
| Suga, H | 1 |
| Shun, C | 1 |
| Yong-Yi, J | 1 |
| Mei-Li, C | 1 |
| Shi-Li, L | 1 |
| Jian-Bo, Z | 1 |
| Dan-Li, W | 1 |
| Zhi-Min, G | 1 |
| Ibrahim, AM | 1 |
| Zakhary, SY | 1 |
| Amin, SAW | 1 |
| Ugurlu, M | 1 |
| Fornari, VJ | 1 |
| Hartmann, MSM | 1 |
| Vanni, JR | 1 |
| Rodriguez, R | 1 |
| Langaro, MC | 1 |
| Pelepenko, LE | 1 |
| Zaia, AA | 1 |
| Nakanjako, D | 1 |
| Zalwango, F | 1 |
| Wairagala, P | 1 |
| Luboga, F | 1 |
| Andia Biraro, I | 1 |
| Bukirwa, VD | 1 |
| Mboowa, MG | 1 |
| Cose, S | 1 |
| Seeley, J | 1 |
| Elliott, A | 1 |
| Zhao, G | 1 |
| Sun, P | 1 |
| Hao, S | 1 |
| Wang, X | 1 |
| Qu, G | 1 |
| Xing, Y | 1 |
| Xu, X | 1 |
| Maierhofer, M | 1 |
| Rieger, V | 1 |
| Mayr, T | 1 |
| Liu, Y | 2 |
| Zhang, Q | 1 |
| Bigliardi, AP | 1 |
| Fernandes, CLF | 1 |
| Pinto, EA | 1 |
| Dos Santos, M | 1 |
| Garcia, EM | 1 |
| Baisch, PRM | 1 |
| Soares, MCF | 1 |
| Muccillo-Baisch, AL | 1 |
| da Silva Júnior, FMR | 1 |
| Yu, W | 1 |
| Ju, C | 2 |
| Wang, K | 2 |
| Zheng, Z | 1 |
| Liu, H | 1 |
| Gao, Y | 1 |
| Martínez-Navarro, EM | 1 |
| Cebrián-Tarancón, C | 1 |
| Moratalla-López, N | 1 |
| Lorenzo, C | 1 |
| Alonso, GL | 1 |
| Salinas, RM | 1 |
| Bermúdez de Castro, JM | 1 |
| Modesto-Mata, M | 1 |
| Martín-Francés, L | 1 |
| García-Campos, C | 1 |
| Martínez de Pinillos, M | 1 |
| Martinón-Torres, M | 1 |
| Hasani, M | 1 |
| Wu, F | 2 |
| Warriner, K | 1 |
| Kurz, M | 1 |
| Gretzke, D | 1 |
| Hörlein, R | 1 |
| Turpault, S | 1 |
| Atzrodt, J | 1 |
| Derdau, V | 1 |
| Yao, Y | 1 |
| Ou, X | 1 |
| Zhao, S | 1 |
| Tian, B | 1 |
| Jin, S | 1 |
| Jiang, Z | 1 |
| Zhou, Z | 1 |
| Liu, M | 2 |
| Jiang, GD | 1 |
| Mou, LH | 1 |
| Chen, JJ | 1 |
| Li, ZY | 1 |
| He, SG | 1 |
| Reale, E | 1 |
| Fustinoni, S | 1 |
| Mercadante, R | 1 |
| Polledri, E | 1 |
| Hopf, NB | 1 |
| Grant, PC | 1 |
| Levy, K | 1 |
| Lattimer, TA | 1 |
| Depner, RM | 1 |
| Kerr, CW | 1 |
| Sato, J | 1 |
| Merenda, MEZ | 1 |
| Uemoto, AT | 1 |
| Dos Santos, MP | 1 |
| Barion, MRL | 1 |
| Carciofi, AC | 1 |
| de Paula Dorigam, JC | 1 |
| Ribeiro, LB | 1 |
| Vasconcellos, RS | 1 |
| Waller, SB | 1 |
| Peter, CM | 1 |
| Hoffmann, JF | 1 |
| Cleff, MB | 1 |
| Faria de, RO | 1 |
| Zani, JL | 1 |
| Martins, BA | 1 |
| Sande, D | 1 |
| Solares, MD | 1 |
| Takahashi, JA | 1 |
| Yang, S | 2 |
| Jia, Y | 1 |
| Yin, C | 1 |
| Zhao, R | 1 |
| Ojha, M | 1 |
| Wu, B | 1 |
| Deepa, M | 1 |
| Mo, J | 1 |
| Au, DW | 1 |
| Wan, MT | 1 |
| Shi, J | 1 |
| Zhang, G | 1 |
| Winkler, C | 1 |
| Kong, RY | 1 |
| Seemann, F | 1 |
| Bianco, M | 1 |
| Calvano, CD | 1 |
| Ventura, G | 1 |
| Bianco, G | 1 |
| Losito, I | 1 |
| Cataldi, TRI | 1 |
| Angiolella, L | 1 |
| Staudt, A | 1 |
| Duarte, PF | 1 |
| Amaral, BPD | 1 |
| Peixoto Andrade, BCO | 1 |
| Simas, NK | 1 |
| Correa Ramos Leal, I | 1 |
| Sangenito, LS | 1 |
| Santos, ALSD | 1 |
| de Oliveira, D | 1 |
| Junges, A | 1 |
| Cansian, RL | 1 |
| Paroul, N | 1 |
| Siu, J | 1 |
| Klingler, L | 1 |
| Hung, CT | 1 |
| Jeong, SH | 1 |
| Smith, S | 1 |
| Tingle, MD | 1 |
| Wagner Mackenzie, B | 1 |
| Biswas, K | 1 |
| Douglas, RG | 1 |
| Oza, AM | 1 |
| Lorusso, D | 1 |
| Aghajanian, C | 1 |
| Oaknin, A | 1 |
| Dean, A | 1 |
| Colombo, N | 1 |
| Weberpals, JI | 1 |
| Clamp, AR | 1 |
| Scambia, G | 1 |
| Leary, A | 1 |
| Holloway, RW | 1 |
| Gancedo, MA | 1 |
| Fong, PC | 1 |
| Goh, JC | 1 |
| O'Malley, DM | 1 |
| Armstrong, DK | 1 |
| Banerjee, S | 1 |
| García-Donas, J | 1 |
| Swisher, EM | 1 |
| Cella, D | 1 |
| Meunier, J | 1 |
| Goble, S | 1 |
| Cameron, T | 1 |
| Maloney, L | 1 |
| Mörk, AC | 1 |
| Bedel, J | 1 |
| Ledermann, JA | 1 |
| Coleman, RL | 1 |
| Vlek, SL | 1 |
| Burm, R | 1 |
| Govers, TM | 1 |
| Vleugels, MPH | 1 |
| Tuynman, JB | 1 |
| Mijatovic, V | 1 |
| Leicht, AS | 1 |
| Connor, J | 1 |
| Conduit, N | 1 |
| Vaquera, A | 1 |
| Gómez, MA | 1 |
| McKay, JA | 1 |
| Church, AL | 1 |
| Rubin, N | 1 |
| Emory, TH | 1 |
| Hoven, NF | 1 |
| Kuehn-Hajder, JE | 1 |
| Nelson, MT | 1 |
| Ramanna, S | 1 |
| Auerbach, EJ | 1 |
| Moeller, S | 1 |
| Bolan, PJ | 1 |
| Fox, NP | 1 |
| Leonard, M | 1 |
| Sjerps, MJ | 1 |
| Chang, EF | 1 |
| Hyun, S | 1 |
| Saejio, A | 1 |
| Shanmugam, S | 1 |
| Liu, X | 2 |
| Sun, M | 1 |
| Bai, Z | 1 |
| Jaque-Fernandez, F | 1 |
| Beaulant, A | 1 |
| Berthier, C | 1 |
| Monteiro, L | 1 |
| Allard, B | 1 |
| Casas, M | 1 |
| Rieusset, J | 1 |
| Jacquemond, V | 1 |
| Góngora-García, OR | 1 |
| Aca-Aca, G | 1 |
| Baz-Rodríguez, SA | 1 |
| Monte, A | 1 |
| Maganaris, C | 1 |
| Baltzopoulos, V | 1 |
| Zamparo, P | 1 |
| Wang, Z | 2 |
| Hou, Y | 1 |
| Cai, L | 1 |
| Tu, YJ | 1 |
| Tan, B | 1 |
| Jiang, L | 1 |
| Wu, ZH | 1 |
| Yu, HJ | 1 |
| Li, XQ | 1 |
| Yang, AD | 1 |
| Titze, IR | 1 |
| Palaparthi, A | 1 |
| Mau, T | 1 |
| González, MA | 1 |
| Goiri, F | 1 |
| Barandika, JF | 1 |
| García-Pérez, AL | 1 |
| Jatt, LP | 1 |
| Gandhi, MM | 1 |
| Guo, R | 1 |
| Sukhija-Cohen, A | 1 |
| Bhattacharya, D | 1 |
| Tseng, CH | 1 |
| Chew, KW | 1 |
| Onwumere, J | 1 |
| Pia Tek, J | 1 |
| Budnyak, T | 1 |
| Budnyk, S | 1 |
| Karim, Z | 1 |
| Thersleff, T | 1 |
| Kuśtrowski, P | 1 |
| Mathew, AP | 1 |
| Slabon, A | 1 |
| Guo, M | 1 |
| Zhao, T | 1 |
| Xing, Z | 1 |
| Qiu, Y | 1 |
| Pan, K | 1 |
| Li, Z | 3 |
| Zhou, W | 1 |
| Ghassemi Tabrizi, S | 1 |
| Arbuznikov, AV | 1 |
| Jiménez-Hoyos, CA | 1 |
| Kaupp, M | 1 |
| Lin, MH | 2 |
| Bulman, DM | 1 |
| Remucal, CK | 1 |
| Chaplin, BP | 1 |
| Laguerre, A | 1 |
| George, LA | 1 |
| Gall, ET | 1 |
| Emerson, MS | 1 |
| Wang, H | 3 |
| Maginn, EJ | 1 |
| Margulis, CJ | 1 |
| Li, H | 2 |
| Feng, W | 1 |
| Kang, X | 2 |
| Yan, S | 1 |
| Chao, M | 1 |
| Mo, S | 1 |
| Sun, W | 1 |
| Lu, Y | 1 |
| Chen, C | 1 |
| Stevens, DM | 1 |
| Adiseshaiah, P | 1 |
| Dasa, SSK | 1 |
| Potter, TM | 1 |
| Skoczen, SL | 1 |
| Snapp, KS | 1 |
| Cedrone, E | 1 |
| Patel, N | 1 |
| Busman-Sahay, K | 1 |
| Rosen, EP | 1 |
| Sykes, C | 1 |
| Cottrell, M | 1 |
| Dobrovolskaia, MA | 1 |
| Estes, JD | 1 |
| Kashuba, ADM | 1 |
| Stern, ST | 1 |
| Özütemiz, C | 1 |
| Neil, EC | 1 |
| Tanwar, M | 1 |
| Rubin, NT | 1 |
| Ozturk, K | 1 |
| Cayci, Z | 1 |
| Duscha, BD | 1 |
| Kraus, WE | 1 |
| Jones, WS | 1 |
| Robbins, JL | 1 |
| Piner, LW | 1 |
| Huffman, KM | 1 |
| Allen, JD | 1 |
| Annex, BH | 1 |
| Mehmood, T | 1 |
| Ahmad, I | 1 |
| Bibi, S | 1 |
| Mustafa, B | 1 |
| Ali, I | 1 |
| Dahal, RH | 1 |
| Chaudhary, DK | 1 |
| Kim, DU | 1 |
| Kim, J | 1 |
| Yeter, HH | 1 |
| Gonul, I | 1 |
| Guz, G | 1 |
| Helvaci, O | 1 |
| Korucu, B | 1 |
| Akcay, OF | 1 |
| Derici, U | 1 |
| Arinsoy, T | 1 |
| Neffati, R | 1 |
| Judeinstein, P | 1 |
| Rault, J | 1 |
| Xu, Y | 1 |
| Chai, X | 1 |
| Ren, T | 1 |
| Yu, S | 1 |
| Fu, Q | 2 |
| Ye, J | 1 |
| Ge, X | 1 |
| Song, J | 1 |
| Yang, H | 2 |
| El-Baba, TJ | 1 |
| Lutomski, CA | 1 |
| Kantsadi, AL | 1 |
| Malla, TR | 1 |
| John, T | 1 |
| Mikhailov, V | 1 |
| Bolla, JR | 1 |
| Schofield, CJ | 1 |
| Zitzmann, N | 1 |
| Vakonakis, I | 1 |
| Robinson, CV | 1 |
| Langham, MC | 1 |
| Caporale, AS | 1 |
| Wehrli, FW | 1 |
| Parry, S | 1 |
| Schwartz, N | 1 |
| den Boer, RB | 1 |
| Jones, KI | 1 |
| Ash, S | 1 |
| van Boxel, GI | 1 |
| Gillies, RS | 1 |
| O'Donnell, T | 1 |
| Ruurda, JP | 1 |
| Sgromo, B | 1 |
| Silva, MA | 1 |
| Maynard, ND | 1 |
| Sivieri, EM | 1 |
| Eichenwald, EC | 1 |
| Rub, D | 1 |
| Abbasi, S | 1 |
| Krahnert, I | 1 |
| Bolze, A | 1 |
| Gibon, Y | 1 |
| Fernie, AR | 1 |
| Huang, L | 1 |
| Wan, Y | 1 |
| Dang, Z | 1 |
| Yang, P | 1 |
| Yang, Q | 1 |
| Wu, S | 2 |
| Lin, CC | 1 |
| Hsu, CT | 1 |
| Liu, W | 2 |
| Huang, SC | 1 |
| Kortz, U | 1 |
| Mougharbel, AS | 1 |
| Chen, TY | 1 |
| Hu, CW | 1 |
| Lee, JF | 1 |
| Wang, CC | 1 |
| Liao, YF | 1 |
| Li, LJ | 1 |
| Li, L | 1 |
| Peng, S | 1 |
| Stimming, U | 1 |
| Hebbar Kannur, K | 1 |
| Yaqub, TB | 1 |
| Pupier, C | 1 |
| Héau, C | 1 |
| Cavaleiro, A | 1 |
| Yamamoto, S | 2 |
| Ono, A | 1 |
| Matsui, J | 1 |
| Hoshino, N | 1 |
| Akutagawa, T | 1 |
| Miyashita, T | 1 |
| Mitsuishi, M | 1 |
| Patel, SM | 1 |
| Smith, TG | 1 |
| Morton, M | 1 |
| Stiers, KM | 1 |
| Seravalli, J | 1 |
| Mayclin, SJ | 1 |
| Edwards, TE | 1 |
| Tanner, JJ | 1 |
| Becker, DF | 1 |
| Butcher, TW | 1 |
| Yang, JL | 1 |
| Hartwig, JF | 1 |
| Yu, MF | 1 |
| Xia, ZZ | 1 |
| Yao, JC | 1 |
| Feng, Z | 1 |
| Li, DH | 1 |
| Liu, T | 1 |
| Cheng, GJ | 1 |
| He, DL | 1 |
| Li, XH | 1 |
| Huurman, R | 1 |
| Schinkel, AFL | 1 |
| de Jong, PL | 1 |
| van Slegtenhorst, MA | 1 |
| Hirsch, A | 1 |
| Michels, M | 1 |
| Kataja, A | 1 |
| Tarvasmäki, T | 1 |
| Lassus, J | 1 |
| Sionis, A | 1 |
| Mebazaa, A | 1 |
| Pulkki, K | 1 |
| Banaszewski, M | 1 |
| Carubelli, V | 1 |
| Hongisto, M | 1 |
| Jankowska, E | 1 |
| Jurkko, R | 1 |
| Jäntti, T | 1 |
| Kasztura, M | 1 |
| Parissis, J | 1 |
| Sabell, T | 1 |
| Silva-Cardoso, J | 1 |
| Spinar, J | 2 |
| Tolppanen, H | 1 |
| Harjola, VP | 1 |
| Carsetti, A | 1 |
| Damiani, E | 1 |
| Casarotta, E | 1 |
| Scorcella, C | 1 |
| Domizi, R | 1 |
| Gasparri, F | 1 |
| Gabbanelli, V | 1 |
| Pantanetti, S | 1 |
| Carozza, R | 1 |
| Adrario, E | 1 |
| Donati, A | 1 |
| Almada, E | 1 |
| Pariani, A | 1 |
| Rivabella Maknis, T | 1 |
| Hidalgo, F | 1 |
| Vena, R | 1 |
| Favre, C | 1 |
| Larocca, MC | 1 |
| Lu, ZY | 1 |
| Jiang, WD | 1 |
| Wu, P | 1 |
| Kuang, SY | 1 |
| Tang, L | 1 |
| Yang, J | 1 |
| Zhou, XQ | 1 |
| Feng, L | 1 |
| Leal, M | 1 |
| Zampini, IC | 1 |
| Mercado, MI | 1 |
| Moreno, MA | 1 |
| Simirgiotis, MJ | 1 |
| Bórquez, J | 1 |
| Ponessa, G | 1 |
| Isla, MI | 1 |
| Saliu, IO | 1 |
| Amoo, ZA | 1 |
| Khan, MF | 1 |
| Olaleye, MT | 1 |
| Rema, V | 1 |
| Akinmoladun, AC | 1 |
| Khan, AU | 1 |
| Rahman, AU | 1 |
| Yuan, Q | 1 |
| Ahmad, A | 1 |
| Khan, ZUH | 1 |
| Mahnashi, MH | 1 |
| Alyami, BA | 1 |
| Alqahtani, YS | 1 |
| Ullah, S | 1 |
| Wirman, AP | 1 |
| Gao, M | 1 |
| Deng, L | 1 |
| Zhang, K | 1 |
| Wang, M | 2 |
| Xia, Z | 1 |
| Gao, D | 1 |
| Balkissou, AD | 1 |
| Poka-Mayap, V | 1 |
| Massongo, M | 1 |
| Djenabou, A | 1 |
| Endale-Mangamba, LM | 1 |
| Olomo, EJ | 1 |
| Boulleys-Nana, JR | 1 |
| Diffo-Sonkoue, L | 1 |
| Adidigue-Ndiome, R | 1 |
| Alexandra, AJE | 1 |
| Haman-Wabi, AB | 1 |
| Adama, S | 1 |
| Iddi-Faical, A | 1 |
| Pefura-Yone, EW | 1 |
| Zhao, Q | 1 |
| Tong, W | 1 |
| Ge, C | 1 |
| Zhao, D | 1 |
| Norbäck, D | 1 |
| Li, B | 1 |
| Zhao, Z | 1 |
| Huang, C | 1 |
| Zhang, X | 1 |
| Qian, H | 1 |
| Yang, X | 1 |
| Sun, Y | 1 |
| Sundell, J | 1 |
| Deng, Q | 1 |
| Kim, HJ | 1 |
| Jeon, JW | 1 |
| Hwang, SM | 1 |
| Chu, KI | 1 |
| Cha, YH | 1 |
| Kwak, YD | 1 |
| Choi, SD | 1 |
| Aslam, M | 1 |
| Kim, CG | 1 |
| Zhou, J | 1 |
| Yang, E | 1 |
| Yang, W | 1 |
| Fuchs, FD | 1 |
| Scala, LCN | 1 |
| Vilela-Martin, JF | 1 |
| Whelton, PK | 1 |
| Poli-de-Figueiredo, CE | 1 |
| Pereira E Silva, R | 1 |
| Gus, M | 1 |
| Bortolotto, LA | 1 |
| Consolim-Colombo, FM | 1 |
| Schlatter, RP | 1 |
| Cesarino, JE | 1 |
| Castro, I | 1 |
| Figueiredo Neto, JA | 1 |
| Chaves, H | 1 |
| Steffens, AA | 1 |
| Alves, JG | 1 |
| Brandão, AA | 1 |
| de Sousa, MR | 1 |
| Jardim, PC | 1 |
| Moreira, LB | 1 |
| Franco, RS | 1 |
| Gomes, MM | 1 |
| Afiune Neto, A | 1 |
| Fuchs, FC | 1 |
| Sobral Filho, DC | 1 |
| Nóbrega, AC | 1 |
| Nobre, F | 1 |
| Berwanger, O | 1 |
| Fuchs, SC | 1 |
| Aung, TKK | 1 |
| Chuah, TY | 1 |
| Chua, MWJ | 1 |
| Parvanova, A | 1 |
| Trillini, M | 1 |
| Podestà, MA | 1 |
| Iliev, IP | 1 |
| Ruggiero, B | 1 |
| Abbate, M | 1 |
| Perna, A | 2 |
| Peraro, F | 1 |
| Diadei, O | 1 |
| Rubis, N | 1 |
| Gaspari, F | 1 |
| Carrara, F | 1 |
| Stucchi, N | 1 |
| Belviso, A | 1 |
| Bossi, AC | 1 |
| Trevisan, R | 1 |
| Remuzzi, G | 14 |
| de Borst, M | 1 |
| Ruggenenti, P | 4 |
| Eltablawy, N | 1 |
| Ashour, H | 1 |
| Rashed, LA | 1 |
| Hamza, WM | 1 |
| Su, Z | 1 |
| Widomski, D | 1 |
| Nikkel, A | 1 |
| Leys, L | 1 |
| Namovic, M | 1 |
| Donnelly-Roberts, D | 1 |
| Gopalakrishnan, M | 1 |
| McGaraughty, S | 1 |
| Sabry, MM | 1 |
| Mahmoud, MM | 1 |
| Shoukry, HS | 1 |
| Rashed, L | 1 |
| Kamar, SS | 1 |
| Ahmed, MM | 1 |
| Tahara, A | 1 |
| Takasu, T | 1 |
| Rabizadeh, S | 1 |
| Dehghani Firouzabadi, F | 1 |
| Noshad, S | 1 |
| Esteghamati, S | 1 |
| Afarideh, M | 1 |
| Ghajar, A | 1 |
| Ganji, M | 1 |
| Saadat, M | 1 |
| Heidari, B | 1 |
| Najafi, MT | 1 |
| Nakhjavani, M | 1 |
| Esteghamati, A | 1 |
| Castoldi, G | 1 |
| di Gioia, CRT | 1 |
| Roma, F | 1 |
| Carletti, R | 1 |
| Manzoni, G | 1 |
| Stella, A | 1 |
| Zerbini, G | 1 |
| Perseghin, G | 1 |
| Looker, HC | 1 |
| Mauer, M | 2 |
| Saulnier, PJ | 3 |
| Harder, JL | 1 |
| Nair, V | 1 |
| Boustany-Kari, CM | 1 |
| Guarnieri, P | 1 |
| Hill, J | 1 |
| Esplin, CA | 1 |
| Kretzler, M | 1 |
| Nelson, RG | 6 |
| Najafian, B | 1 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Maeda, K | 1 |
| Otoshi, K | 1 |
| Fukuda, M | 2 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Kato, S | 1 |
| Baba, Y | 1 |
| Weil, EJ | 4 |
| Fufaa, G | 1 |
| Jones, LI | 2 |
| Lovato, T | 2 |
| Lemley, KV | 4 |
| Hanson, RL | 2 |
| Knowler, WC | 3 |
| Bennett, PH | 2 |
| Yee, B | 3 |
| Myers, BD | 3 |
| Rauch, G | 1 |
| Beyersmann, J | 1 |
| Okin, PM | 2 |
| Hille, DA | 2 |
| Wiik, BP | 2 |
| Kjeldsen, SE | 3 |
| Lindholm, LH | 2 |
| Dahlöf, B | 4 |
| Devereux, RB | 5 |
| Jennifer Weil, E | 1 |
| Nagata, T | 1 |
| Fukuzawa, T | 1 |
| Takeda, M | 1 |
| Fukazawa, M | 1 |
| Mori, T | 1 |
| Nihei, T | 1 |
| Honda, K | 1 |
| Suzuki, Y | 2 |
| Kawabe, Y | 1 |
| Briasoulis, A | 1 |
| Oliva, R | 1 |
| Kalaitzidis, R | 1 |
| Flynn, C | 1 |
| Lazich, I | 1 |
| Schlaffer, C | 1 |
| Bakris, G | 1 |
| Nicholas, SB | 1 |
| Iyengar, SK | 1 |
| Vitovec, J | 1 |
| Soucek, M | 1 |
| Smink, PA | 1 |
| Miao, Y | 3 |
| Eijkemans, MJ | 1 |
| Bakker, SJ | 3 |
| Raz, I | 1 |
| Parving, HH | 22 |
| Hoekman, J | 1 |
| Grobbee, DE | 2 |
| de Zeeuw, D | 23 |
| Lambers Heerspink, HJ | 8 |
| Reddy, MA | 1 |
| Sumanth, P | 1 |
| Lanting, L | 1 |
| Yuan, H | 1 |
| Mar, D | 1 |
| Bomsztyk, K | 1 |
| Natarajan, R | 1 |
| Nishida, Y | 1 |
| Takahashi, Y | 1 |
| Susa, N | 1 |
| Kanou, N | 1 |
| Nakayama, T | 1 |
| Asai, S | 1 |
| Weldegiorgis, M | 1 |
| Inker, LA | 1 |
| Gansevoort, R | 1 |
| Dwyer, JP | 1 |
| Mondal, H | 1 |
| Coresh, J | 1 |
| Greene, T | 1 |
| Levey, AS | 1 |
| Arnoni, CP | 1 |
| Maquigussa, E | 1 |
| Passos, CS | 1 |
| Pereira, LG | 1 |
| Boim, MA | 1 |
| Riphagen, IJ | 1 |
| Deetman, PE | 1 |
| Navis, G | 1 |
| Cooper, ME | 19 |
| Lewis, JB | 6 |
| Woo, KT | 1 |
| Choong, HL | 1 |
| Wong, KS | 2 |
| Tan, HK | 1 |
| Foo, M | 1 |
| Fook-Chong, S | 1 |
| Lee, EJ | 1 |
| Anantharaman, V | 1 |
| Lee, GS | 1 |
| Chan, CM | 1 |
| Kakimoto, T | 1 |
| Okada, K | 1 |
| Hirohashi, Y | 1 |
| Relator, R | 1 |
| Kawai, M | 1 |
| Iguchi, T | 1 |
| Fujitaka, K | 1 |
| Nishio, M | 1 |
| Kato, T | 1 |
| Fukunari, A | 1 |
| Utsumi, H | 1 |
| Okada, Y | 1 |
| Mori, H | 1 |
| Nishida, K | 1 |
| Uriu, K | 1 |
| Tanaka, Y | 1 |
| Pozzobon, CR | 3 |
| Gismondi, RA | 3 |
| Bedirian, R | 3 |
| Ladeira, MC | 3 |
| Neves, MF | 3 |
| Oigman, W | 3 |
| Hull, TD | 1 |
| Agarwal, A | 1 |
| Imbalzano, E | 1 |
| Scarpelli, M | 1 |
| Mandraffino, G | 1 |
| Creazzo, M | 1 |
| Lizio, G | 1 |
| Trapani, G | 1 |
| Dattilo, G | 1 |
| Dalbeni, A | 1 |
| Tomasello, C | 1 |
| Sardo, MA | 1 |
| Saitta, A | 1 |
| Jourdan, T | 1 |
| Szanda, G | 1 |
| Rosenberg, AZ | 1 |
| Tam, J | 1 |
| Earley, BJ | 1 |
| Godlewski, G | 1 |
| Cinar, R | 1 |
| Liu, Z | 1 |
| Pacher, P | 1 |
| Kunos, G | 1 |
| Schievink, B | 1 |
| Rossing, P | 5 |
| Schutte, E | 1 |
| Lutgers, HL | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Gansevoort, RT | 1 |
| Derosa, G | 5 |
| Querci, F | 2 |
| Franzetti, I | 2 |
| Dario Ragonesi, P | 1 |
| D'Angelo, A | 3 |
| Maffioli, P | 3 |
| Meyer zum Gottesberge, AM | 1 |
| Massing, T | 1 |
| Sasse, A | 1 |
| Palma, S | 1 |
| Hansen, S | 1 |
| Husarek, KE | 1 |
| Katz, PS | 1 |
| Trask, AJ | 1 |
| Galantowicz, ML | 1 |
| Cismowski, MJ | 1 |
| Lucchesi, PA | 1 |
| Mugellini, A | 4 |
| Pesce, RM | 2 |
| Cicero, AF | 1 |
| Tocci, G | 1 |
| Felix Kröpelin, T | 1 |
| Holtkamp, FA | 3 |
| Packham, DK | 1 |
| L Heerspink, HJ | 1 |
| Xu, HZ | 1 |
| Wang, WN | 1 |
| Cheng, YL | 1 |
| Xu, ZG | 1 |
| Zhu, Q | 1 |
| Qi, X | 1 |
| Pena, MJ | 1 |
| Heinzel, A | 1 |
| Dallmann, G | 1 |
| Rossing, K | 1 |
| Andersen, S | 1 |
| Mayer, B | 1 |
| Heerspink, HJ | 2 |
| Wheelock, KM | 2 |
| Howell, S | 1 |
| Tanamas, SK | 2 |
| Beisswenger, PJ | 1 |
| Fufaa, GD | 1 |
| Zhu, X | 1 |
| Zhang, C | 1 |
| Fan, Q | 1 |
| Yang, G | 1 |
| Jiang, Y | 1 |
| Muñoz, MC | 1 |
| Burghi, V | 1 |
| Miquet, JG | 1 |
| Cervino, IA | 1 |
| Quiroga, DT | 1 |
| Mazziotta, L | 1 |
| Dominici, FP | 1 |
| Persson, F | 3 |
| Lewis, EJ | 4 |
| Hollenberg, NK | 3 |
| Ingelfinger, JR | 1 |
| Narita, T | 2 |
| Hosoba, M | 1 |
| Miura, T | 2 |
| Sasaki, H | 1 |
| Morii, T | 2 |
| Fujita, H | 2 |
| Kakei, M | 1 |
| Ito, S | 1 |
| Yuan, KL | 1 |
| Shi, XZ | 1 |
| Lu, X | 1 |
| Gao, P | 1 |
| Xu, GW | 1 |
| Kloner, RA | 1 |
| Neutel, J | 1 |
| Roth, EM | 1 |
| Weiss, R | 1 |
| Weinberger, MH | 1 |
| Thakker, KM | 1 |
| Schwartz, B | 1 |
| Shi, H | 2 |
| Gregg, AM | 1 |
| Renke, M | 1 |
| Rutkowski, P | 1 |
| Tylicki, L | 1 |
| Zietkiewicz, M | 1 |
| Larczyński, W | 1 |
| Rutkowski, B | 1 |
| Ikeda, H | 2 |
| Hamamoto, Y | 2 |
| Honjo, S | 2 |
| Nabe, K | 2 |
| Wada, Y | 2 |
| Koshiyama, H | 2 |
| Minamikawa, J | 1 |
| Nakamura, Y | 1 |
| Fried, LF | 1 |
| Duckworth, W | 1 |
| Zhang, JH | 1 |
| O'Connor, T | 1 |
| Brophy, M | 1 |
| Emanuele, N | 1 |
| Huang, GD | 1 |
| McCullough, PA | 1 |
| Seliger, S | 1 |
| Warren, SR | 1 |
| Peduzzi, P | 1 |
| Guo, LL | 1 |
| Pan, Y | 3 |
| Jin, HM | 3 |
| Takahashi, K | 1 |
| Senador, D | 1 |
| Kanakamedala, K | 1 |
| Irigoyen, MC | 1 |
| Morris, M | 1 |
| Elased, KM | 1 |
| Kjaer, A | 1 |
| Kristoffersen, US | 1 |
| Tarnow, L | 1 |
| Hesse, B | 1 |
| Uzu, T | 1 |
| Sakaguchi, M | 1 |
| Yokomaku, Y | 1 |
| Kume, S | 1 |
| Kanasaki, M | 1 |
| Isshiki, K | 1 |
| Araki, SI | 1 |
| Sugiomoto, T | 1 |
| Koya, D | 1 |
| Haneda, M | 1 |
| Kashiwagi, A | 1 |
| Kohlmann, O | 2 |
| Roca-Cusachs, A | 2 |
| Laurent, S | 2 |
| Schmieder, RE | 2 |
| Wenzel, RR | 2 |
| Fogari, R | 4 |
| Agha, A | 2 |
| Amer, W | 1 |
| Anwar, E | 2 |
| Bashir, K | 2 |
| Bichu, P | 1 |
| Nistala, R | 1 |
| Khan, A | 1 |
| Sowers, JR | 1 |
| Whaley-Connell, A | 1 |
| Tepliakov, AT | 1 |
| Maianskaia, SD | 1 |
| Bolotskaia, LA | 1 |
| Vdovina, TV | 1 |
| Stepacheva, TA | 1 |
| Kuznetsova, AV | 1 |
| Lukinov, AV | 1 |
| Derbeneva, NV | 1 |
| Frants, MV | 1 |
| Shilov, SN | 1 |
| Marshall, SM | 1 |
| Arase, Y | 1 |
| Suzuki, F | 1 |
| Akuta, N | 1 |
| Kobayashi, M | 2 |
| Kawamura, Y | 1 |
| Yatsuji, H | 1 |
| Sezaki, H | 1 |
| Hosaka, T | 1 |
| Hirakawa, M | 1 |
| Saito, S | 1 |
| Ikeda, K | 1 |
| Kumada, H | 1 |
| Kobayashi, T | 8 |
| González F, F | 1 |
| Fuentes C, V | 1 |
| Castro H, C | 1 |
| Santelices L, JP | 1 |
| Lorca H, E | 1 |
| Delea, TE | 1 |
| Sofrygin, O | 1 |
| Palmer, JL | 1 |
| Lau, H | 1 |
| Munk, VC | 1 |
| Sung, J | 1 |
| Charney, A | 1 |
| Sullivan, SD | 1 |
| Weir, MR | 4 |
| Yeh, F | 1 |
| Silverman, A | 1 |
| Galloway, JM | 1 |
| Henderson, JA | 1 |
| Howard, WJ | 1 |
| Russell, M | 1 |
| Wilson, C | 1 |
| Ratner, R | 1 |
| Sorkin, J | 1 |
| Umans, JG | 1 |
| Fleg, JL | 1 |
| Stylianou, M | 1 |
| Lee, E | 1 |
| Howard, BV | 1 |
| Matsumoto, T | 7 |
| Ozawa, Y | 1 |
| Taguchi, K | 8 |
| Kamata, K | 7 |
| Hotta, H | 1 |
| Miki, T | 1 |
| Togashi, N | 1 |
| Maeda, T | 1 |
| Kim, SJ | 1 |
| Tanno, M | 1 |
| Yano, T | 1 |
| Kuno, A | 1 |
| Itoh, T | 1 |
| Satoh, T | 1 |
| Terashima, Y | 1 |
| Ishikawa, S | 1 |
| Shimamoto, K | 1 |
| Ishida, K | 4 |
| Hoque, R | 1 |
| Rahman, MS | 1 |
| Iqbal, M | 1 |
| Deb, DK | 1 |
| Sun, T | 1 |
| Wong, KE | 1 |
| Zhang, Z | 21 |
| Ning, G | 1 |
| Kong, J | 1 |
| Chang, A | 1 |
| Li, YC | 1 |
| Nakayama, N | 1 |
| Tan, F | 1 |
| Mukherjee, JJ | 1 |
| Lee, KO | 1 |
| Lim, P | 1 |
| Liew, CF | 1 |
| Dong, YF | 1 |
| Lai, ZF | 1 |
| Yamamoto, E | 1 |
| Kataoka, K | 1 |
| Nakamura, T | 2 |
| Tokutomi, Y | 1 |
| Nako, H | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Larstorp, AC | 1 |
| Høieggen, A | 3 |
| Olsen, MH | 2 |
| Ibsen, H | 3 |
| Lindholm, L | 1 |
| Wachtell, K | 2 |
| Agarwal, R | 2 |
| Fujiwara, N | 1 |
| Sato, E | 1 |
| Ueda, Y | 1 |
| Sugaya, T | 1 |
| Koide, H | 1 |
| Rahimi, Z | 1 |
| Felehgari, V | 1 |
| Rahimi, M | 1 |
| Mozafari, H | 1 |
| Yari, K | 1 |
| Vaisi-Raygani, A | 1 |
| Rezaei, M | 1 |
| Malek-Khosravi, S | 1 |
| Khazaie, H | 1 |
| Dobre, D | 1 |
| Brenner, BM | 26 |
| Shahinfar, S | 29 |
| Grobbee, D | 1 |
| Titan, SM | 1 |
| Zatz, R | 1 |
| Graciolli, FG | 1 |
| dos Reis, LM | 1 |
| Barros, RT | 1 |
| Jorgetti, V | 1 |
| Moysés, RM | 1 |
| Sjølie, AK | 1 |
| Dodson, P | 1 |
| Hobbs, FR | 1 |
| de Graeff, PA | 2 |
| Laverman, GD | 2 |
| Berl, T | 1 |
| Packham, D | 1 |
| Balink, H | 1 |
| Hemmelder, MH | 1 |
| de Graaf, W | 1 |
| Grond, J | 1 |
| Thomas, MC | 1 |
| Hillege, HJ | 1 |
| Ottenbros, SA | 1 |
| Gonçalves, AR | 1 |
| El Nahas, AM | 1 |
| Chang, CH | 1 |
| Lin, JW | 1 |
| Wu, LC | 1 |
| Lai, MS | 1 |
| Fyhrquist, F | 1 |
| Silventoinen, K | 1 |
| Saijonmaa, O | 1 |
| Kontula, K | 1 |
| de Faire, U | 1 |
| Os, I | 2 |
| Destro, M | 1 |
| Corradi, L | 2 |
| Lazzari, P | 2 |
| Zoppi, A | 2 |
| Preti, P | 2 |
| Sakamoto, T | 1 |
| Komatsu, K | 1 |
| Fujishima, H | 1 |
| Takahashi, T | 1 |
| Yamada, Y | 1 |
| Nemoto, S | 1 |
| Dhaun, N | 1 |
| Webb, DJ | 1 |
| Rasi Hashemi, S | 1 |
| Noshad, H | 1 |
| Tabrizi, A | 1 |
| Mobasseri, M | 1 |
| Tayebi Khosroshahi, H | 1 |
| Heydarnejad, M | 1 |
| Khalaj, MR | 1 |
| Aghamohammadzadeh, N | 1 |
| Adam, WR | 1 |
| Ring, T | 1 |
| Hirsch, S | 1 |
| Min, LJ | 1 |
| Mogi, M | 1 |
| Shudou, M | 1 |
| Jing, F | 1 |
| Tsukuda, K | 1 |
| Ohshima, K | 1 |
| Iwanami, J | 1 |
| Horiuchi, M | 1 |
| Liang, J | 1 |
| Leung, KK | 1 |
| Lam, SY | 1 |
| Leung, PS | 3 |
| Mourad, AA | 1 |
| Heeba, GH | 1 |
| Taye, A | 1 |
| El-Moselhy, MA | 1 |
| Mason, CC | 1 |
| Blouch, K | 1 |
| Richardson, M | 1 |
| Satchell, SC | 1 |
| Lim, SC | 2 |
| Liu, JJ | 1 |
| Subramaniam, T | 2 |
| Sum, CF | 2 |
| Kavgaci, H | 1 |
| Sahin, A | 1 |
| Onder Ersoz, H | 1 |
| Erem, C | 1 |
| Ozdemir, F | 1 |
| Zanella, MT | 1 |
| Ribeiro, AB | 3 |
| Rachmani, R | 1 |
| Levi, Z | 1 |
| Zadok, BS | 1 |
| Ravid, M | 1 |
| Suzuki, H | 3 |
| Dickson, TZ | 4 |
| Ahmed, T | 1 |
| Ramjit, D | 4 |
| Smith, RD | 1 |
| Gerth, WC | 4 |
| Viberti, G | 1 |
| Hannedouche, T | 2 |
| Martinez-Castelao, A | 1 |
| Carides, GW | 7 |
| Brenner, B | 1 |
| Eberhard, R | 1 |
| Dikow, R | 2 |
| Carswell, CI | 1 |
| Goa, KL | 1 |
| Herman, WH | 2 |
| Dasbach, EJ | 2 |
| Alexander, CM | 3 |
| Cook, JR | 1 |
| Keane, WF | 15 |
| Lyle, PA | 7 |
| Souchet, T | 1 |
| Durand Zaleski, I | 1 |
| Rodier, M | 1 |
| Gaugris, S | 1 |
| Passa, P | 1 |
| Zandbergen, AA | 3 |
| Baggen, MG | 2 |
| Lamberts, SW | 3 |
| Bootsma, AH | 3 |
| Ouwendijk, RJ | 1 |
| Knudsen, ST | 1 |
| Bek, T | 1 |
| Poulsen, PL | 1 |
| Hove, MN | 1 |
| Rehling, M | 1 |
| Mogensen, CE | 2 |
| Bakris, GL | 2 |
| Shanifar, S | 1 |
| Douglas, J | 1 |
| van Dijk, DJ | 1 |
| Sidorenko, BA | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Stetsenko, TM | 1 |
| Tarykina, EV | 1 |
| Tsurko, VV | 1 |
| Postma, MJ | 1 |
| Kruidhof, H | 1 |
| de Jong-van den Berg, LT | 1 |
| McCall, AL | 1 |
| Kubba, S | 1 |
| Agarwal, SK | 1 |
| Prakash, A | 1 |
| Puri, V | 1 |
| Babbar, R | 1 |
| Anuradha, S | 1 |
| Bramlage, P | 1 |
| Wittchen, HU | 1 |
| Pittrow, D | 1 |
| Kirch, W | 1 |
| Lehnert, H | 1 |
| Ritz, E | 1 |
| Onuigbo, MA | 1 |
| Gleim, GW | 4 |
| Tressler, CS | 1 |
| Ruilope, LM | 3 |
| Segura, J | 1 |
| Foreman, BH | 1 |
| Chambliss, ML | 1 |
| Rayner, B | 1 |
| Chan, JC | 4 |
| Wat, NM | 1 |
| So, WY | 2 |
| Lam, KS | 1 |
| Chua, CT | 1 |
| Morad, Z | 1 |
| Hille, D | 1 |
| Kurokawa, K | 4 |
| Kanno, Y | 2 |
| Kaneko, K | 2 |
| Kaneko, M | 2 |
| Kotaki, S | 2 |
| Mimura, T | 2 |
| Takane, H | 2 |
| Mandal, AK | 1 |
| Kario, K | 1 |
| Shimada, K | 1 |
| Snapinn, S | 2 |
| Mitch, WE | 5 |
| Burgess, ED | 1 |
| Marentette, MA | 1 |
| Chabot, I | 1 |
| Sasaki, M | 1 |
| Uehara, S | 1 |
| Ohta, H | 1 |
| Kemi, M | 1 |
| Nishikibe, M | 1 |
| Matsumoto, H | 1 |
| Dawson, A | 1 |
| Rana, BS | 1 |
| Pringle, SD | 1 |
| Donnelly, LA | 1 |
| Morris, AD | 1 |
| Struthers, AD | 1 |
| Cetinkaya, R | 1 |
| Odabas, AR | 1 |
| Selcuk, Y | 1 |
| Perico, N | 1 |
| Leung, WY | 1 |
| Tong, PC | 1 |
| Lo, MK | 1 |
| Lee, KF | 1 |
| Ko, GT | 1 |
| Chan, WB | 1 |
| Cockram, CS | 2 |
| Critchley, JA | 2 |
| Fox, JC | 1 |
| Leight, K | 1 |
| Sutradhar, SC | 1 |
| Demopoulos, LA | 1 |
| Lewin, AJ | 1 |
| Ouyang, JP | 1 |
| Zhou, YF | 1 |
| Wu, K | 1 |
| Zhao, DH | 1 |
| Wen, CY | 1 |
| Mohanram, A | 2 |
| Toto, RD | 2 |
| Szucs, TD | 1 |
| Sandoz, MS | 1 |
| Keusch, GW | 1 |
| Dimitrov, BD | 1 |
| Singh, RB | 1 |
| Cornelissen, G | 1 |
| Halberg, F | 1 |
| Otsuka, K | 1 |
| Egan, B | 1 |
| Gleim, G | 1 |
| Panish, J | 1 |
| Fossum, E | 1 |
| Hjerkinn, E | 1 |
| Nesbitt, SD | 1 |
| Andersen, UB | 1 |
| Phillips, RA | 1 |
| Gaboury, CL | 1 |
| Julius, S | 1 |
| Kowey, PR | 3 |
| Doggrell, SA | 2 |
| Snapinn, SM | 4 |
| Yasuda, G | 1 |
| Ando, D | 1 |
| Hirawa, N | 1 |
| Umemura, S | 1 |
| Tochikubo, O | 1 |
| Luño, J | 1 |
| Boner, G | 1 |
| McCarroll, K | 1 |
| Dickson, T | 1 |
| Crow, RS | 1 |
| Rodríguez-Iturbe, B | 1 |
| Quiroz, Y | 1 |
| Shahkarami, A | 1 |
| Seng, WK | 1 |
| Hwang, SJ | 1 |
| Han, DC | 1 |
| Teong, CC | 1 |
| Chan, J | 2 |
| Burke, TA | 1 |
| Choi, YJ | 1 |
| Pershadsingh, HA | 1 |
| Carr, AA | 1 |
| Edelman, JM | 1 |
| Burnier, M | 1 |
| Zanchi, A | 1 |
| Janssen, JA | 2 |
| Boersma, E | 1 |
| Chu, KY | 2 |
| Lau, T | 1 |
| Carlsson, PO | 2 |
| Lash, JP | 1 |
| Baumgart, P | 1 |
| Igarashi, M | 1 |
| Hirata, A | 1 |
| Kadomoto, Y | 1 |
| Tominaga, M | 1 |
| Park, H | 1 |
| Hasegawa, G | 1 |
| Obayashi, H | 1 |
| Fujinami, A | 1 |
| Ohta, M | 1 |
| Hara, H | 1 |
| Adachi, T | 1 |
| Tamaki, S | 1 |
| Nakajima, Y | 1 |
| Kimura, F | 1 |
| Ogata, M | 1 |
| Fukui, M | 1 |
| Yoshikawa, T | 1 |
| Nakamura, N | 1 |
| Yoshizumi, M | 2 |
| Ishizawa, K | 2 |
| Izawa, Y | 1 |
| Tamaki, T | 2 |
| Winkelmayer, WC | 1 |
| Avorn, J | 1 |
| Kimura, G | 1 |
| Bakkum, JN | 1 |
| Brost, BC | 1 |
| Johansen, KL | 1 |
| Johnston, BW | 1 |
| Watson, WJ | 1 |
| Deyneli, O | 1 |
| Yavuz, D | 1 |
| Velioglu, A | 1 |
| Cacina, H | 1 |
| Aksoy, N | 1 |
| Haklar, G | 1 |
| Taga, Y | 1 |
| Akalin, S | 1 |
| Woo, V | 1 |
| Ni, LS | 1 |
| Hak, D | 1 |
| Berard, L | 1 |
| Zhu, F | 1 |
| Khan, S | 1 |
| Ma, GM | 1 |
| Penner, B | 1 |
| Shen, GX | 1 |
| Flammer, AJ | 1 |
| Hermann, F | 1 |
| Wiesli, P | 1 |
| Schwegler, B | 1 |
| Chenevard, R | 1 |
| Hürlimann, D | 1 |
| Sudano, I | 1 |
| Gay, S | 1 |
| Neidhart, M | 1 |
| Riesen, W | 1 |
| Ruschitzka, F | 1 |
| Lüscher, TF | 1 |
| Noll, G | 1 |
| Lehmann, R | 1 |
| Eijkelkamp, WB | 1 |
| Koh, AF | 1 |
| Goh, SK | 1 |
| Chua, CL | 1 |
| Heng, BL | 1 |
| Petkow-Dimitrow, P | 1 |
| Sawaki, H | 1 |
| Terasaki, J | 1 |
| Fujita, A | 1 |
| Nakagawa, S | 1 |
| Kanatsuna, N | 1 |
| Sadahiro, K | 1 |
| Isotani, H | 1 |
| Imagawa, A | 1 |
| Hanafusa, T | 1 |
| Abe, H | 1 |
| Minatoguchi, S | 1 |
| Ohashi, H | 1 |
| Murata, I | 1 |
| Minagawa, T | 1 |
| Okuma, T | 1 |
| Yokoyama, H | 1 |
| Takatsu, H | 1 |
| Takaya, T | 1 |
| Nagano, T | 1 |
| Osumi, Y | 1 |
| Kakami, M | 1 |
| Tsukamoto, T | 1 |
| Tanaka, T | 1 |
| Hiei, K | 1 |
| Fujiwara, H | 1 |
| Tershakovec, AM | 1 |
| Appel, GB | 1 |
| McGill, JB | 2 |
| Tufescu, A | 1 |
| Kanazawa, M | 1 |
| Ishida, A | 1 |
| Sasaki, Y | 1 |
| Ootaka, T | 1 |
| Sato, T | 1 |
| Kohzuki, M | 1 |
| Liu, N | 1 |
| Lunceford, J | 1 |
| Wong, PH | 1 |
| Triposkiadis, F | 1 |
| Lee, JH | 1 |
| Xia, S | 1 |
| Ragolia, L | 1 |
| Ottlecz, A | 1 |
| Bensaoula, T | 1 |
| Eichberg, J | 1 |
| Peterson, RG | 1 |
| Tomlinson, B | 1 |
| Chan, TY | 1 |
| van der Meulen, J | 1 |
| Cleophas, TJ | 1 |
| Zwinderman, AH | 1 |
| Carlson, SH | 1 |
| Shelton, J | 1 |
| White, CR | 1 |
| Wyss, JM | 1 |
| Lacourcière, Y | 1 |
| Bélanger, A | 1 |
| Godin, C | 1 |
| Hallé, JP | 1 |
| Ross, S | 1 |
| Wright, N | 1 |
| Marion, J | 1 |
| Cheetham, C | 2 |
| Collis, J | 1 |
| O'Driscoll, G | 2 |
| Stanton, K | 2 |
| Taylor, R | 2 |
| Green, D | 2 |
| Lozano, JV | 1 |
| Llisterri, JL | 1 |
| Aznar, J | 1 |
| Redon, J | 1 |
| Esmatjes, E | 1 |
| Flores, L | 1 |
| Iñigo, P | 1 |
| Lario, S | 1 |
| Campistol, JM | 1 |
| Coats, AJ | 1 |
| Bloomgarden, ZT | 1 |
| Kurtzman, NA | 1 |
| Jerums, G | 3 |
| Gilbert, RE | 2 |
| Atkins, RC | 1 |
| Tsuchiya, K | 1 |
| Takishita, E | 1 |
| Nakaya, Y | 1 |
| Kishi, K | 1 |
| Ebina, Y | 1 |
| Houchi, H | 1 |
| Minakuchi, K | 1 |
| Murali, B | 1 |
| Goyal, RK | 1 |
| Pierce, HL | 1 |
| Stevermer, JJ | 1 |
| Farquhar, D | 1 |
| Beevers, DG | 1 |
| Lip, GY | 1 |
| Nilsson, P | 1 |
| Attvall, S | 1 |
| Tütüncü, NB | 1 |
| Gürlek, A | 1 |
| Gedik, O | 1 |
| Walser, M | 1 |
| Ceriello, A | 1 |
| Motz, E | 1 |
| Swift, PA | 1 |
| MacGregor, GA | 1 |
| de Pablos-Velasco, PL | 1 |
| Pazos Toral, F | 1 |
| Esmatjes, JE | 1 |
| Fernandez-Vega, F | 1 |
| Lopez de la Torre, ML | 1 |
| Pozuelo, A | 1 |
| Houlihan, CA | 2 |
| Allen, TJ | 1 |
| Baxter, AL | 1 |
| Panangiotopoulos, S | 1 |
| Casley, DJ | 1 |
| Grunfeld, JP | 1 |
| Schluchter, MD | 1 |
| Snavely, D | 1 |
| Simpson, R | 1 |
| Lindenfeld, J | 1 |
| Borer, J | 1 |
| Armstrong, PW | 1 |
| Konstam, MA | 1 |
| Akdeniz, A | 1 |
| Tsalamandris, C | 1 |
| Stenehjem, A | 1 |
| Draganov, B | 1 |
| Jenssen, T | 1 |
| Holdaas, H | 1 |
| Goicolea, I | 1 |
| Fernández González, R | 1 |
| Piniés, J | 1 |
| Garrido, J | 1 |
| Martínez, JM | 1 |
| Armenteros, S | 1 |
| Moreno Carretero, E | 1 |
| Kuhlmann, MK | 1 |
| Köhler, H | 1 |
| Tan, K | 1 |
| Chow, WS | 1 |
| Wong, Y | 1 |
| Shiu, S | 1 |
| Tam, S | 1 |
| Wiedermann, CJ | 1 |
| Bursztyn, M | 1 |
| Hjelmesaeth, J | 1 |
| Bloom, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparison Between Diuretics and Angiotensin-receptor Blocker Agents in Patients With Stage I Hypertension: PREVER-treatment Study[NCT00971165] | Phase 3 | 655 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Prospective, Randomized, Cross-over, Double-blind, Placebo-controlled Study to Assess the Antiproteinuric Effect of Selective Vitamin d Receptor Activation by Paricalcitol in Type 2 Diabetes Patients on Low or High Sodium Diet and Stable Ras Inhibitor T[NCT01393808] | Phase 2 | 112 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Renoprotection in Early Diabetic Nephropathy in Pima Indians[NCT00340678] | Phase 3 | 170 participants (Actual) | Interventional | 1995-08-31 | Completed | ||
| Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up[NCT02064218] | 0 participants | Observational | 2007-11-30 | Recruiting | |||
| Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients With Blood Pressure Not Controlled by Amlodipine: Effects on Echocardiographic Parameters, Vascular Stiffness and Endothelial Function.[NCT01603940] | Phase 4 | 30 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria[NCT00097955] | Phase 2 | 496 participants | Interventional | 2004-10-31 | Completed | ||
| CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)[NCT00555217] | Phase 3 | 1,448 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to It was stopped primarily because of safety concerns along with low conditional power to detect a treatment effect on the primary outcome.) | ||
| Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus[NCT00419835] | Phase 4 | 80 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| No Pharmacokinetic Interaction Between Chlorthalidone and Losartan, in Healthy Volunteers Under Fasting Conditions, Administered in Fixed Combination Against Individual Components Administered Jointly and Separately[NCT05090449] | Phase 1 | 36 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| [NCT03019848] | Phase 2 | 100 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| Using a Diabetic Kidney Disease (DKD) Registry to Treat to Multiple Targets (TMT) (DKD-TMT)[NCT02176278] | 2,400 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| HYZAAR Versus Ramipril Diabetic Patients[NCT00480805] | Phase 3 | 312 participants (Actual) | Interventional | 2001-08-08 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy[NCT00295555] | Phase 4 | 98 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.[NCT00437775] | 300 participants | Observational | 2007-01-31 | Recruiting | |||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)[NCT05037695] | Phase 4 | 40 participants (Anticipated) | Interventional | 2021-07-21 | Recruiting | ||
| Determinants of Diabetic Nephropathy in American Indians[NCT01878045] | 141 participants (Actual) | Observational | 2013-11-07 | Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00340678)
Timeframe: 6 years after first treatment
| Intervention | *10^6 cubic microns (Mean) |
|---|---|
| Normoalbuminuria Losartan | 5.4 |
| Normoalbuminuria Placebo | 5.6 |
| Microalbuminuria Losartan | 6.4 |
| Microalbuminuria Placebo | 7.0 |
Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation. (NCT00340678)
Timeframe: Up to 6 years
| Intervention | participants (Number) |
|---|---|
| Normoalbuminuria Losartan | 2 |
| Normoalbuminuria Placebo | 2 |
| Microalbuminuria Losartan | 1 |
| Microalbuminuria Placebo | 4 |
Compare both group effects on diastolic blood pressure. (NCT01603940)
Timeframe: 12 weeks
| Intervention | mmHg (Median) |
|---|---|
| Losartan | 80 |
| Benazepril | 82 |
Access endothelial function by brachial flow-mediated vasodilation (FMD) and compare it between groups (losartan and benazepril) and its relationship to current statin use. (NCT01603940)
Timeframe: 12 weeks
| Intervention | percentage of maximal vasodilation (Median) |
|---|---|
| Losartan | 9.4 |
| Benazepril | 8.8 |
Compare both groups effects on systolic blood pressure. (NCT01603940)
Timeframe: 12 weeks
| Intervention | mmHg (Median) |
|---|---|
| Losartan | 134 |
| Benazepril | 139 |
Access vascular stiffness by pulse wave velocity and compare it between groups (losartan and benazepril). (NCT01603940)
Timeframe: 12 weeks.
| Intervention | m/s (Median) |
|---|---|
| Losartan | 8.5 |
| Benazepril | 8.5 |
Estimate vascular stiffness by measuring augmentation index and compare it between losartan and benazepril groups. (NCT01603940)
Timeframe: 12 weeks
| Intervention | percentage of augmentation pressure (Median) |
|---|---|
| Losartan | 28 |
| Benazepril | 35 |
Time to the first event of reduction in estimated GFR of 30ml/min/1.73m*m in individuals w/a baseline estimated GFR >= 60 ml/min/1.73m*m, reduction in estimated GFR >50% in individuals w/ baseline estimated GFR <60ml/min/1.73m*m; ESRD or death. (NCT00555217)
Timeframe: From enrollemnt to time of first primary event, up to 4.5 years
| Intervention | participants (Number) |
|---|---|
| Combination of ARB and ACEI | 132 |
| Monotherapy ARB | 152 |
Time to the first event of reduction in estimated GFR of >50% (for individuals with baseline GFR <60) or reduction in GFR of >30 (for individuals with baseline GFR >= GFR 60) or ESRD. (NCT00555217)
Timeframe: From enrollment to time of first event, up to 4.5 years
| Intervention | participants (Number) |
|---|---|
| Combination of ARB and ACEI | 77 |
| Monotherapy ARB | 101 |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
30 reviews available for losartan and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
[Multi-national clinical trial in circulatory disorders].
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-B | 2009 |
Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diabe | 2009 |
Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2011 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2011 |
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2002 |
[Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; | 2002 |
Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2002 |
Losartan in diabetic nephropathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; | 2003 |
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Topics: Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney | 2003 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2003 |
Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diab | 2003 |
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial | 2003 |
Clinical inquiries. Are ARBs or ACE inhibitors preferred for nephropathy in diabetes?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diab | 2004 |
Advances in the treatment of diabetic renal disease: focus on losartan.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2004 |
Losartan in diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabe | 2004 |
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
Topics: Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Health Care | 2004 |
Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Dise | 2005 |
[Renin-angiotensin system in diabetic nephropathy].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2005 |
Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Tri | 2006 |
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 2006 |
Losartan: lessons learned from the RENAAL study.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cli | 2006 |
Time to abandon microalbuminuria?
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; | 2006 |
[Intracellular signal transduction of vascular injury in insulin resistance].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; | 2006 |
[New therapeutic targets for ACE inhibitors and angiotensin receptor blockers].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotens | 2007 |
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2001 |
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; D | 2001 |
Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2001 |
[Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
Topics: Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calci | 2002 |
120 trials available for losartan and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension and diabetes mellitus: results from the PREVER-treatment randomized controlled trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Brazil; Chlorthalidone; Diabetes Me | 2021 |
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.
Topics: Aged; Albuminuria; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Sodium-Restricted; Double-Bl | 2018 |
Beneficial Effects of Pentoxifylline Plus Losartan Dual Therapy in Type 2 Diabetes with Nephropathy.
Topics: Atrial Natriuretic Factor; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dr | 2018 |
Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes.
Topics: Adult; Albuminuria; Analysis of Variance; Biopsy, Needle; Diabetes Mellitus, Type 2; Diabetic Nephro | 2019 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Indians, North Ameri | 2013 |
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Comorbidity; Diabetes Mellitus, Type 2; D | 2013 |
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converti | 2013 |
Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study).
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2014 |
Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Ty | 2014 |
Aliskiren and losartan trial in non-diabetic chronic kidney disease.
Topics: Amides; Blood Pressure; Comorbidity; Demography; Diabetes Mellitus, Type 2; Dose-Response Relationsh | 2014 |
Type 2 diabetes mellitus complicated by hypertension in Japanese patients: switching treatment from high-dose angiotensin II receptor blockers to losartan plus hydrochlorothiazide.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Com | 2014 |
Functional vascular study in hypertensive subjects with type 2 diabetes using losartan or amlodipine.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2014 |
Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.
Topics: Aged; Albuminuria; Amides; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diastole; Drug The | 2015 |
Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A randomized controlled trial.
Topics: Aorta; Benzazepines; Blood Pressure; C-Reactive Protein; Cohort Studies; Diabetes Mellitus, Type 2; | 2015 |
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Blood Pr | 2015 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus.
Topics: Adipokines; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2015 |
Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial.
Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines | 2015 |
Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics.
Topics: Amino Acids; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazep | 2015 |
Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; | 2016 |
Clinical study of total glucosides of paeony for the treatment of diabetic kidney disease in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Crea | 2016 |
Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glycat | 2016 |
Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial.
Topics: Adult; Albumins; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; | 2016 |
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Amides; Angiotensin II Type 1 Receptor Bloc | 2008 |
Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Dr | 2008 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; | 2009 |
Comparison of effects of amlodipine and angiotensin receptor blockers on the intima-media thickness of carotid arterial wall (AAA study: amlodipine vs. ARB in atherosclerosis study).
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Carotid Arterie | 2009 |
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus | 2009 |
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Topics: Adiponectin; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabe | 2009 |
Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Coronary Circulation; Diabetes | 2009 |
Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Circadian Rh | 2009 |
Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Ty | 2009 |
Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus | 2009 |
[Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiotonic Agents; C | 2009 |
Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial.
Topics: Aged; Algorithms; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2009 |
Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients.
Topics: Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enalapril; Humans; | 2009 |
Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2010 |
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hy | 2010 |
Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabet | 2010 |
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.
Topics: Aged; Albuminuria; Amides; Antihypertensive Agents; Creatinine; Diabetes Mellitus, Type 2; Diabetic | 2010 |
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; | 2011 |
FGF-23 as a predictor of renal outcome in diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2011 |
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.
Topics: Aged; Albuminuria; Amides; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabe | 2011 |
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Creatinine; Diab | 2011 |
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathi | 2011 |
Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2011 |
Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2012 |
Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antioxidant | 2011 |
Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
Topics: Acetylcysteine; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Dia | 2012 |
Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy.
Topics: Adult; Albuminuria; Antihypertensive Agents; Biopsy; Capillaries; Diabetes Mellitus, Type 2; Diabeti | 2012 |
Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2014 |
The effects of losartan and fosinopril in hypertensive type 2 diabetic patients.
Topics: Adult; Alanine Transaminase; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspa | 2002 |
Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study.
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Antioxidants; Cross-Over Studies; Diabet | 2002 |
Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Creatinine; Diabetes | 2002 |
Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
Losartan in diabetic nephropathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; | 2003 |
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
Topics: Aged; Antihypertensive Agents; Cost Savings; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fema | 2003 |
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Topics: Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney | 2003 |
An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France.
Topics: Antihypertensive Agents; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Dia | 2003 |
Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2 | 2003 |
Effects of losartan on diabetic maculopathy in type 2 diabetic patients: a randomized, double-masked study.
Topics: Aged; Angiotensin Receptor Antagonists; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Retinopa | 2003 |
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2003 |
Reducing CVD risk in type 2 DM.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normotensive microalbuminuric type 2 diabetics.
Topics: Adult; Albuminuria; Antihypertensive Agents; Autonomic Nervous System Diseases; Diabetes Mellitus, T | 2003 |
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.
Topics: Antihypertensive Agents; Asian People; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2004 |
Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium; Diabetes Mellitus, | 2004 |
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2004 |
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2004 |
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2004 |
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2004 |
Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Canada; Cost Savings; Diabetes Mellitus, Type 2; Diab | 2004 |
Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2004 |
Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type | 2004 |
The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asian People; Creatinine; Critical Care; Diabetes Mel | 2004 |
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
Topics: Aged; Albuminuria; Angina, Unstable; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Cardiovasc | 2004 |
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chi-Square Distribution; Diabetes | 2004 |
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.
Topics: Aged; Anemia; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Pr | 2004 |
The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Cost of Illness; Cost Savings; Cost-Benefit An | 2004 |
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
Topics: Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Health Care | 2004 |
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
Topics: Aged; Antihypertensive Agents; Cost Savings; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fema | 2004 |
Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Topics: Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Metho | 2004 |
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; F | 2005 |
Losartan and end-organ protection--lessons from the RENAAL study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Mellitus, Ty | 2005 |
Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy.
Topics: Adult; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 2005 |
Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Topics: Aged; Angiotensin II; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Diab | 2005 |
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Cost-Benefit Analysi | 2005 |
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Creatinine; Diabetes Mellitus, | 2006 |
Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2006 |
Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; F | 2006 |
Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fe | 2006 |
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Creatinine; | 2006 |
Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients.
Topics: Acetylglucosaminidase; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibi | 2006 |
Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; C-Peptide; Calcium | 2007 |
Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Coagulation Factors; Blood | 2006 |
Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Cross-Over Studies; Diabetes Mel | 2007 |
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Topics: Aged; Albuminuria; Angiotensin II; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2007 |
Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Com | 2007 |
Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angio | 2007 |
A renoprotective effect of low dose losartan in patients with type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Mass Index; D | 2008 |
Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2007 |
The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.
Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2008 |
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; | 2008 |
Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Co | 2008 |
Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Ca | 1997 |
Replacement of angiotensin-converting enzyme inhibitors by angiotensin-II-receptor antagonists in hypertensive patients with type II diabetes mellitus: metabolic and hemodynamic consequences.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 1999 |
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neph | 2000 |
Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes.
Topics: Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium; Femal | 2000 |
Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Cross-Over Studies; Diabetes Mellitus, Type 2; Doub | 2001 |
Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, | 2001 |
Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Topics: Adult; Aged; Angiotensin II; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Ty | 2001 |
Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2001 |
Losartan titration versus diuretic combination in type 2 diabetic patients.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellit | 2002 |
A low-sodium diet potentiates the effects of losartan in type 2 diabetes.
Topics: Albuminuria; Aldosterone; Angiotensin II; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cr | 2002 |
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
Topics: Aged; Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Bl | 2000 |
Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, Type 2; Female | 2002 |
Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood | 2002 |
[Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study].
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2002 |
Effect of losartan on plasma C-reactive protein in type 2 diabetic patients with microabluminuria.
Topics: Albuminuria; Antihypertensive Agents; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephro | 2002 |
116 other studies available for losartan and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators.
Topics: AMP-Activated Protein Kinases; Animals; Benzimidazoles; Biphenyl Compounds; Cattle; Diabetes Mellitu | 2019 |
Pathophysiological analysis of uninephrectomized db/db mice as a model of severe diabetic kidney disease.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; | 2022 |
Tetrahydrocurcumin Add-On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury.
Topics: Animals; Antioxidants; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2023 |
Unilateral nephrectomized SHR/NDmcr-cp rat shows a progressive decline of glomerular filtration with tubular interstitial lesions.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Losartan; Metabolic Syndrome; Rats; Rats | 2023 |
Protective effects of losartan on some type 2 diabetes mellitus-induced complications in Wistar and spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Brain; Corticosterone; Diabetes Mellitus, Experime | 2020 |
Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Ne | 2020 |
More Than Meets the Eye: A Patient with Hand Swelling and Newly Diagnosed Diabetes Mellitus.
Topics: Aged; Amlodipine; Anemia; Antihypertensive Agents; Blood Sedimentation; C-Reactive Protein; Diabetes | 2021 |
Vitamin D protection from rat diabetic nephropathy is partly mediated through Klotho expression and renin-angiotensin inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarker | 2018 |
Losartan improves renal function and pathology in obese ZSF-1 rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cholesterol; Diabetes Mellitus, Experi | 2018 |
Interactive effects of apelin, renin-angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apelin; Biomarkers; Blood Glucose; Diabetes Mellit | 2019 |
Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2018 |
Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty rats.
Topics: Animals; Blood Glucose; Cardiomegaly; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Di | 2019 |
Planning and evaluating clinical trials with composite time-to-first-event endpoints in a competing risk framework.
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Clinical Trials as Topic; Computer Simulat | 2013 |
Is endothelial dysfunction more deleterious than podocyte injury in diabetic nephropathy?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Glomerulus; Losartan; Male | 2013 |
The authors reply.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Glomerulus; Losartan; Male | 2013 |
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzhydryl Compounds; Biomarkers; Blo | 2013 |
Does losartan prevent progression of early diabetic nephropathy in American Indians with type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Losartan; Male | 2013 |
The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitu | 2014 |
Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cells, Cultured; Chemokine CCL2; C | 2014 |
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mel | 2013 |
Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cell Movement; Cell Transdifferentiation; Chole | 2015 |
Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Bilirubin; Biphenyl Compounds; Diabetes Mellitus, Typ | 2014 |
Automated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Glucose; Body Weight; Desmin; Di | 2014 |
Bilirubin: a potential biomarker and therapeutic target for diabetic nephropathy.
Topics: Bilirubin; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Ir | 2014 |
Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy.
Topics: Analysis of Variance; Angiotensin II; Animals; Arachidonic Acids; Desmin; Diabetes Mellitus, Type 2; | 2014 |
Zucker diabetic fatty rats, a model for type 2 diabetes, develop an inner ear dysfunction that can be attenuated by losartan treatment.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hearing Loss; Hyperglycemia; La | 2015 |
The angiotensin receptor blocker losartan reduces coronary arteriole remodeling in type 2 diabetic mice.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arterioles; Blood Pressure; Coronary Vess | 2016 |
Metabolic approaches to antihypertensive treatment in diabetic patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium | 2015 |
Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, T | 2016 |
Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; | 2016 |
Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, Type 2; | 2016 |
Inhibiting MicroRNA-503 and MicroRNA-181d with Losartan Ameliorates Diabetic Nephropathy in KKAy Mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Kidney | 2016 |
Chronic blockade of the AT2 receptor with PD123319 impairs insulin signaling in C57BL/6 mice.
Topics: Adiponectin; Adipose Tissue; Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Chemo | 2017 |
Aliskiren and dual therapy in type 2 diabetes mellitus.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; | 2008 |
Low dose of losartan decreased urinary excretions of IgG, transferrin, and ceruloplasmin without reducing albuminuria in normoalbuminuric type 2 diabetic patients.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Ceruloplasmin; Diabetes Mellit | 2008 |
[Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics].
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Biomarkers; Chromatography, Gas; Creatinine; Deoxyguanosin | 2007 |
[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type | 2008 |
Cardiovascular and autonomic phenotype of db/db diabetic mice.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Nervous System; B | 2009 |
Intensive diabetes management for high-risk patients: how best to deliver?
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Delivery of Health Ca | 2009 |
Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C.
Topics: Aged; Antihypertensive Agents; Asian People; Case-Control Studies; Data Interpretation, Statistical; | 2009 |
[Economic impact of Losartan use in type 2 diabetic patients with nephropathy].
Topics: Angiotensin II Type 1 Receptor Blockers; Chile; Cost of Illness; Cost-Benefit Analysis; Diabetes Mel | 2009 |
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Topics: Albuminuria; Amides; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic | 2009 |
Chronic treatment with losartan (angiotensin II type 1 receptor antagonist) normalizes enhanced acetylcholine-induced coronary vasoconstriction in isolated perfused hearts of type 2 diabetic OLETF rats.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Coronary Vessels; Cyclic N-Oxides; | 2009 |
Angiotensin II type 1 receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcineurin; Diabetes Mellitus, Type 2; Enkephalin | 2010 |
Short-term angiotensin-1 receptor antagonism in type 2 diabetic Goto-Kakizaki rats normalizes endothelin-1-induced mesenteric artery contraction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Endothel | 2010 |
Losartan normalizes endothelium-derived hyperpolarizing factor-mediated relaxation by activating Ca2+-activated K+ channels in mesenteric artery from type 2 diabetic GK rat.
Topics: Animals; Biological Factors; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Endotheliu | 2010 |
Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Crea | 2010 |
Mechanisms underlying the losartan treatment-induced improvement in the endothelial dysfunction seen in mesenteric arteries from type 2 diabetic rats.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Cyclooxygenase 1; Cyclooxygenase 2; | 2010 |
Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice.
Topics: Albuminuria; Amides; Animals; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; D | 2010 |
Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Diabe | 2010 |
The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria.
Topics: Albuminuria; Alleles; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Ca | 2011 |
Scintigraphic diagnosis of Erdheim-Chester disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Erdheim-Che | 2011 |
High serum potassium levels after using losartan can reflect more severe renal disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; | 2011 |
Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabeti | 2011 |
Mechanisms underlying altered extracellular nucleotide-induced contractions in mesenteric arteries from rats in later-stage type 2 diabetes: effect of ANG II type 1 receptor antagonism.
Topics: Adenosine Triphosphate; Angiotensin II Type 1 Receptor Blockers; Animals; Cyclooxygenase 1; Cyclooxy | 2011 |
Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blocker | 2011 |
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; | 2012 |
The therapeutic tradeoff between the adverse impacts of a lower GFR and long-term renal protection.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabeti | 2012 |
Have we observed the implications of the acute fall in eGFR during treatment with losartan?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabeti | 2012 |
Pre-renal success.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabeti | 2012 |
Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Be | 2012 |
Angiotensin II type 2 receptor-dependent increase in nitric oxide synthase activity in the endothelium of db/db mice is mediated via a MEK pathway.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Diabetes Mellitus, Type 2; | 2012 |
Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cell Differentiation; Diabetes Mellitus, Type 2; D | 2012 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, | 2013 |
The glomerular endothelium emerges as a key player in diabetic nephropathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Glomerulus; Losartan; Male | 2012 |
Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
Topics: Angiotensin II Type 1 Receptor Blockers; Cost of Illness; Cost Savings; Cost-Benefit Analysis; Diabe | 2002 |
Angiotensin II receptor blockade in diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2003 |
Summaries for patients. The blood pressure drug losartan appears to benefit the kidneys of people with type 2 diabetes who do not have high blood pressure.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Blood Pressure; Diabetes Mellitus, Type 2; Female; Hu | 2003 |
[Microalbuminuria is an early marker for increased morbidity and mortality].
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biom | 2003 |
Achieved vs initial blood pressure in predicting renal outcomes.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2004 |
Effects of losartan on diabetic maculopathy in type 2 diabetic patients.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; Losartan; Macula Lutea; Tomography; Treatme | 2004 |
Losartan for microalbuminuria in normotensive type 2 diabetes mellitus.
Topics: Albuminuria; Blood Pressure; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Humans; Losartan | 2004 |
Losartan for microalbuminuria in normotensive type 2 diabetes mellitus.
Topics: Albuminuria; Blood Pressure; Diabetes Mellitus, Type 2; Humans; Losartan; Monitoring, Physiologic | 2004 |
Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibit | 2004 |
How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Echocardiography; Electroc | 2004 |
Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Transporter Type 4; Ins | 2004 |
Losartan-ramipril combination treatment.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Heart Rate; Humans; H | 2004 |
[A problem that should be recognized. Greater risk of diabetes with antihypertensive drugs?].
Topics: Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug | 2004 |
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropath | 2005 |
Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2005 |
Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease | 2006 |
Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, T | 2006 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Cos | 2006 |
Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension.
Topics: Anti-Inflammatory Agents; Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Infla | 2006 |
[Plus point -- risk reduction].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents | 2006 |
Japanese subpopulation analysis of the RENAAL, the landmark trial, is welcomed by our society.
Topics: Angiotensin II Type 1 Receptor Blockers; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabet | 2006 |
In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Contraindications; Diabetes Mellitus, Type 2; Female; Fetal | 2006 |
Angiotensin II Type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young Type 2 diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blotting, Western; Caspase 3; Diabetes | 2007 |
Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diabe | 2007 |
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
Topics: Albuminuria; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney Fai | 2008 |
Combination of exercise and losartan enhances renoprotective and peripheral effects in spontaneously type 2 diabetes mellitus rats with nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabeti | 2008 |
Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats.
Topics: Aging; Angiotensin II; Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Endothelium, Vas | 2008 |
Angiotensin-converting enzyme activity in retinas of streptozotocin-induced and Zucker diabetic rats. The effect of angiotensin II on Na+,K(+)-ATPase activity.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Experimenta | 1996 |
Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Glucose; B | 2000 |
Angiotensin II receptor blockers and nephropathy trials.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; | 2001 |
Drug companies should not have the final say in the design of clinical trials.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2001 |
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diab | 2001 |
Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats.
Topics: Adipocytes; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blotting, Western; Body | 2001 |
Improvement in insulin sensitivity by losartan in non-insulin-dependent diabetic (NIDDM) rats.
Topics: Animals; Antihypertensive Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insuli | 2001 |
[Angiotensin II antagonist also protects the kidneys. 2 dialysis-free years for diabetics].
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Kidney Function | 2001 |
Does losartan (Cozaar) slow the progression of renal disease in patients with type 2 diabetes and nephropathy?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Confidence Intervals; Diabetes Mellitus, Type | 2001 |
Angiotensin-Il-receptor blockers and nephropathy in patients with type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2001 |
[Angiotensin II receptor antagonists reduce the development of nephropathies in type 2 diabetes. Three new studies are of interest, but don't answer all questions].
Topics: Angiotensin II; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Follow-U | 2001 |
[Losartan and the kidney protection. The RENAAL study].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2001 |
Preventing nephropathy in patients with type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2002 |
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2002 |
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2002 |
Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as To | 2002 |
Losartan potassium (Cozaar).
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2002 |
Contemporary medical options for treating patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2002 |
[The RENAAL Study. Effect of losartan on diabetic nephropathy].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Melli | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Losartan; Treat | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseases; Diabetes | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type | 2002 |